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Abstract
Towards the systematic evaluation of variable modes of mechanical conditioning on the
compositional, microstructural, and mechanical properties of engineered tissue vascular grafts.
By:

Sarah Kaye Saunders, Ph.D.
A Dissertation submitted in partial fulfillment of the requirements for
the degree of Doctor of Philosophy at Virginia Commonwealth University, 2022.

Advisor:

Dr. Joao de Silva Soares, Ph.D. Assistant Professor,
Department of Mechanical and Nuclear Engineering

Coronary artery bypass surgery (CABG) remains one of the most common cardiac surgical
procedures performed worldwide, frequently involving multiple bypasses, and commonly employing the
patient’s internal mammary artery, radial artery, or saphenous vein. CABG is often not possible because
native vessels were already employed in previous interventions or are diseased themselves. Synthetic
vascular grafts are currently integral tools of vascular surgery and have had relative success in large-caliber
applications providing substantial benefit to aortic or iliac grafting; however, small diameter (< 6 mm)
arterial grafts have not yet translated into clinical effectiveness due to thrombosis and anastomotic intimal
hyperplasia. ETVGs present an exciting potential alternative in vascular grafting by offering a blood vessel
substitute that could exhibit all the functional characteristics of native vasculature. In addition to relieving
supply limitations associated with coronary artery bypass surgery ETVGs are especially ideal for pediatric
patients with congenital heart disease who require grafts that grow as they do, eliminating the need for
reoccurring invasive surgeries.
Though the role of biomechanics in regulating cellular behavior promoting non-thrombogenicity,
vasoactivity, and ECM synthesis and maintenance is well established, scientists have yet to find the

xi

optimum culture conditions to obtain viable small diameter ETVGs suitable for clinical application.
Mechanical conditioning is widely recognized as one of the most relevant methods to enhance tissue
accretion and microstructure, leading to engineered tissues with improved mechanical behaviors. However,
determining optimal conditioning protocols for ETVGs is rather empirical and based on extensive trial-anderror iterations. We are unable to predict this cause-and-effect relationship accurately, and thus unable to
reliably produce ETVGs with targeted properties. This is only magnified when considering the phase after
deployment where the understanding of the in vivo performance of the grafts until it is fully absorbed is
crucial to improve patency.
This dissertation documents the development of protocols for the systematic study of ETVGs
cultured under biaxial mechanical stress. Firstly, we define our chosen ETVG development model and
surgical techniques for in vivo deployment. Tissue engineering scaffolds 2mm in diameter are
manufactured from electrospun PCL and perfusion seeded via bioreactor with rat vascular smooth muscle
cells (VSMCs). Seeded ETVGs cultured in the same bioreactor environment are then implanted into the
abdominal aorta of mature Sprague Dawley rats for a period of up to 2 weeks to observe the acute immune
response to the implant. Histology revealed ETVGs with fully confluent circumferential cell coverage after
in vitro culture. Grafts were able to maintain patency for the short deployment period, and fibrotic tissue
formation was observed around the implant at harvest. Secondly, we refine our bioreactor design and
seeding method to improve consistency between the 4 ETVGs being cultured, a key feature to increase the
statistical significance of each experiment and speed progress in the field. The modifications resulted in
ETVG with 60% surface coverage of viable cells 24 hours after seeding, a significant improvement over
traditionally employed static methods. Finally, we develop protocols to standardize the use of the bioreactor
system for the study of the effects of biaxial mechanical strain on ETVG development. The development
of this vital tool not only marks the transition of vascular tissue engineering from a field of empirical
discovery to one of systematic characterization but contributes significantly towards progress in the field.
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1 Chapter 1

Background and Significance

1.1 Clinical Need
Cardiovascular disease (CVD) is the principal cause of death worldwide and includes disorders
such as peripheral arterial disease, coronary artery disease, cerebrovascular disease and rheumatic heart
disease. A common treatment for a variety of CVD related pathologies is revascularization, where blood
flow is restored to an area previously blocked by injured or pathological vasculature via a vessel like
conduit. Specifically, coronary artery bypass grafting (CABG) remains one of the most common cardiac
surgical procedures performed worldwide, with an estimated 400,000 procedures performed annually in the
US alone1. CABG also represents a unique problem considering revascularization given its classification
as a small diameter (<5mm) vessel. For vessels of a larger diameter, the use of synthetic vessels constructed
from polymers like PTFE or Dacron for revascularization has been met with great success 2,3. However as
the size of the vessel decreases, issues with thrombogenicity and fibrotic immune response become more
pronounced and long term patency becomes increasingly difficult to achieve4.
Autologous grafts represent the current gold standard in vascular bypass with a 10 year patency
rate of 61% and 81% for venous and arterial grafts respectively5. The most commonly employed vessel for
autologous grafting is the saphenous vein, but arterial candidates such as the internal thoracic arteries,
internal mammary artery, radial artery and the gastroepiploic arteries have also been used6 (Fig 1). The
obvious advantages of autologous grafting include the lack of immune response and instant remodeling
potential, but the risk associated with vessel harvesting and the limited supply of available candidates raise
concerns. In fact, for over 30% of patients in need of revascularization the procedure is deemed too
1

dangerous, the necessary vasculature was already employed in previous grafting, or the cardiovascular
pathology has spread to the graft candidates7. These considerations delineate the need for small diameter
vascular grafting alternatives to compensate for the limited supply of autografts and account for patients in
which autografting proves too unsafe to pursue.

Figure 1. Diagram of the physiological locations of common vessels utilized for CABG.
Cases of pediatric vascular reconstruction (PVR) would also benefit from small diameter vascular
grafts that emulate autologous grafts. PVR is rare and the operation is technically difficult given the small
size of the patient and associated considerations like smaller total blood volume, and underdeveloped tissue
2

supporting the structural integrity of the vasculature leading to persistent vasospasms following injury 8. In
children, vascular injury is also typically accompanied by bone, nerve, and soft tissue injuries, meaning that
there is increased risk of stunted development or even loss of limb when complications arise during vascular
surgery9. Additionally, as a pediatric patient grows the implanted graft needs to accommodate for this
development. If an autologous graft is not used, the patient will eventually require additional surgeries to
replace the undersized synthetic graft10. The technical difficulty, lack of procedural resources and high risk
of potentially devastating outcomes associated with PVR are all aspects that could partially be alleviated
by the discovery of a suitable manufacturable bioactive vessel alternative.
Vascular reconstructive surgery of medium sized vessels (> 5 mm) also encounters issues with
patency, though not as severe as small diameter grafts. Medium sized vascular reconstruction is related to
repair of peripheral artery disease or vascular injury, restoring blood flow to the extremities. It is very
common to use synthetic grafts in these applications, but the risk of thrombosis is higher and autologous
vessels are still preferred11,12. Some of the first functional modifications made to synthetic vascular grafts
were anti-thrombotic linings, including a fully developed endothelial cell monolayer13. Another common
application of vascular grafting are arteriovenous fistulas for hemodialysis access. In this application, a
graft is used to connect a vein to an artery in the patients arm so blood can be accessed and circulated
through a hemodialysis machine for filtration. This application comes with additional complications, as it
is constantly punctured for treatment, and consequently prone to developing infection 14. Testing new
vascular graft conduits in these applications is common prior to attempting smaller diameter, high risk
reconstruction trials like CABG.

1.2 Vascular Structure
The cardiovascular system consists of two blood flow circuits connected and driven by the muscular
pump that is the heart15. The pulmonary circuit circulates blood through the lungs for oxygenation then
returns the blood to the heart. The newly oxygenated blood enters the left atrium and travels through the
mitral valve into the left ventricle. Blood is then pumped through the aorta to deliver oxygen and other
3

nutrients throughout the second circuit, the systemic circulatory system. The vessels that carry blood away
from the heart are referred to as arteries. The aorta is the largest artery averaging about 30 mm in diameter,
and as blood travels away from the heart the aorta branches into several smaller arteries that facilitate the
delivery of blood to and from the extremities15. The smallest arteries, called arterioles are the last defined
vessels blood travels through on its way to the capillary beds that facilitate nutrient transfer to tissues, and
they can be as small as 10 µm. Deoxygenated blood then makes its way back to the heart, carrying CO2
and other cellular waste products through the veins.

1.2.1 The Vessel Wall
Blood vessels consist of three layers, the tunica intima, the tunica media and the tunica adventitia15
(Fig 2). The intima is located on the luminal surface of blood vessels and consists of a monolayer of vascular
endothelial cells (EC). The ECs are spindle shaped and aligned in the direction of blood flow16. The purpose
of this layer is to form a protective barrier between blood and tissues by facilitating the passage of certain
molecules and cells from blood to tissues, regulating vascular disease, preventing thrombus formation and
maintaining vascular tone through extracellular signaling17. The intima is supported by and connected to
the media by a thin basement membrane called the internal elastic laminae, a fenestrated membrane of
elastic fibers that contribute to the physical and mass transfer properties of blood vessels. The media layer
is primarily made of vascular smooth muscle cells (VSMCs) and is the thickest layer of the arterial wall.
This layer is a dynamic environment, constantly remodeling to better accommodate changes in blood flow
and pressure18. VSMCs play a major role in maintaining this environment in response to external chemical
and mechanical stimuli. The ECM secreted by VSMCs is primarily made up of collagen to provide
structural support and strength, and elastin to provide compliance and elasticity19. VSMCs orient
themselves into circumferentially aligned concentric rings of lamellar units, in which elastin forms the
dominate compartmental structures housing the VSMCs and collagen is present as circumferentially aligned
parallel bundles weaving through the entire mesh20,21. The media is connected to the adventitia by another
elastic boundary called the external elastic lamina. In venous blood vessels this is the thickest layer, and it
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is primarily composed of fibroblast which synthesize a thick layer of collagen16. This layer is viewed as
connective tissue and anchors blood vessels to the surrounding connective tissue in the environment.

Figure 2. Gross anatomy of the blood vessel wall.
The mechanical properties of the vascular wall are directly related to the composition and structure
of these components. As such the gross morphology between arteries and veins is different. Arteries can be
further divided into two subclasses called elastic and muscular arteries22. Elastic arteries are typically found
near the heart and experience high pressures associate with blood being ejected from the right ventricle.
These vessels contain a higher proportion of elastin in their lamellar units, contributing to a high compliance
and strain capacity. This is essential for regulating blood flow in more distal regions of the vasculature by
providing volume control in response to the pressure gradient. As the size of arteries decrease, the relative
amount of elastin decreases and the number of VSMCs increases, contributing to a stiffer structure. In these
arteries, called the muscular arteries, blood flow is facilitated more by the viscoelastic contractile properties
of VSMCs, which modulates the diameter of the vasculature in response to changes in blood pressure and
flow rate. The ratio of collagen to elastin continues to increase in veins as blood pressure continues to
decrease, while vein diameters are consistently larger than their arterial counterparts23. The tunica media of
veins is much thinner than that of arteries, and there is little contribution to the flow of blood from the
structure itself. Veins contain most of the blood in the circulatory system and are some of the most
distensible vessels in the body, able to accommodate changes in volume without a detrimental increase in
5

blood pressure24,25. An additional feature found in veins, not present in arteries, are valves intermittently
spaced to prevent blood regurgitation.
The composition, structure and mechanical properties of the arterial wall are significantly different
from those in veins, and when used in arterial revascularization venous vascular smooth muscle cells
attempt to remodel the vessel structure to accommodate new arterial stresses. The required remodeling is
typically too extensive, which contributes to the lower patency of venous autografts. Even though decades
of research has demonstrated the use of arteries in vascular reconstruction significantly enhances both short
term and long term mortality in CABG patients, the use of vein grafts still dominates the field26. Concerns
regarding arterial harvest, such as deep sternal wound infection associated with internal thoracic arteries,
limits widespread adoption of the technique. This coupled with the extensive data collected in regard to
saphenous vein grafts showing their reliability and safety contribute to low arterial utilization (< 10%)
within the society of thoracic surgeons’ databases. However, more recent studies regarding utilization of
radial arteries offer lower morbidity associated with harvesting with additional benefits including increased
length and infection resistance, suggesting arterial grafting could eventually increase in popularity.

1.2.2 Vascular Biomechanics
Blood vessels are dynamic structures, constantly remodeling in response to external cues.
There are three main forms of mechanical force constantly acting on a blood vessel: (1) shear stress
of blood flow, (2) circumferential distension by the blood pressure gradient, and (3) axial stretch
mediated by connective tissue anchoring27 (Fig 3). When evaluated as a biomaterial, blood vessels
have unique properties that allow them to respond appropriately to changes in these factors in both
immediate and long-term ways. For example, vascular walls can withstand large levels of
deformation, however as additional pressure is applied and the vessel is distended the vascular
wall becomes rigid and stiff28. Most materials that exhibit strain hardening properties are resistant
to deformation, however, the unique undulation of collagen fibers oriented in the circumferential
6

direction facilitate this interesting characteristic29. In low pressure situations, arteries maintain
compliance and the circumferentially aligned collagen is in a crimped state. With an increase in
pressure and circumferential strain, the collagen fibers straighten out and experience tensile strain,
greatly reducing the vessel elasticity and increasing stiffness.

Figure 3. Diagram of vascular wall dynamics. The 3 primary forms of loading experienced by native
vasculature are flow-induced wall shear stress (τw) , pressure-induced circumferential wall stress (σθ), and
axial load-induced axial wall stress (σz). Copied with permission from [27].

1.2.3 VSMCs and Strain
VSMCs exert direct control over the mechanical properties of blood vessels by modulation of their
contractile state. When activated the Young’s modulus of VSMCs jumps from 10 kPa to 100 kPa, and the
diameter of the vessel constricts. However, as VMSC are consistently exposed to cyclic stress it is important
to take into account other characteristics they have that are not observable in the immediate sense but occur
over time. VSMCs are viscoelastic, meaning they exhibit time dependent strain. This can be majorly
7

attributed to mechanical adaptation of the VSMCs in response to the mechanical cues of their
environment30. Cyclic stretch modulates proliferation, differentiation, and ECM synthesis by VSMCs. It
has been observed that cells respond in equal measure to being over-stressed and under-stressed, while
physiological levels of stress maintain homeostasis and a contractile phenotype31. In response to injury,
VSMC will switch from the contractile phenotype to the synthetic phenotype, to facilitate proliferation and
wound repair. However, if the VSMCs are unable to switch back into the contractile phenotype after repair
is complete, they tend to over proliferate and invade the intimal layer32. This is called intimal hyperplasia,
one of the 6 classifications of atherosclerotic plaques which causes narrowing and occlusion of blood
vessels. In this section what is known about VSMC response to mechanical stimulation is reviewed.
When vascular smooth muscle cells undergo stretch they produce increased levels of h-CaD, a
molecule that helps regulate contractile function. This effect is doubled when VSMCs are cultured on
laminin, suggesting laminin plays an important role in maintaining cell contractility and regulating blood
flow33. Laminin has also been reported to inhibit VSMC proliferation, preventing neointimal hyperplasia34.
Culturing VSMCs on different substrates typically found in the ECM is a method used to study cell-matrix
interactions. Culturing VSMCs on fibronectin followed by the application of a gradient of mechanical
stretch resulted in the migration of smooth muscle cells to stiffer regions, however the same treatment
applied to VSMCs coated on laminin resulted in random migration patterns35,36. This suggests that cell
motility is a response of mechanical stimulation regardless, but migration can be directed by modulating
surface coatings and substrate stiffness. Furthermore, it has been reported that stretch increases DNA
synthesis in VSMCs cultured on fibronectin or vitronectin, but not in VSMCs cultured on elastin, collagen
or laminin37,38. This provides evidence that the mechanism for the upregulation of cell proliferation by
mechano-transduction is dependent on specific integrin-ECM interactions unrelated to the cyclin-dependent
kinase complexes that fill that role in response to growth factors. Cyclic strain has also been demonstrated
to induce TGFb signaling through SMAD pathways, which upregulates ECM synthesis in vascular smooth
muscle cells39.
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More macroscopic observations from ETVGs can be tied to these cellular interactions, such as the
preference of VSMC to align in the direction of the force being applied and subsequent matrix deposition
at the same orientation33. Also, macrophages recruited for wound healing secrete fibronectin, which has
been proven to increase DNA synthesis and directed migration in VSMCs34. By combining the knowledge
of the countless empirical efforts applying mechanical strain to ETVGs and general VSMC biomechanics,
the creation of logical progressive experiments geared toward consistent and reliable manipulation of graft
properties can be achieved.

1.2.4 ECs and Shear Stress
Hemodynamic shear stress on ECs is essential in mediating VSMC contractile state. In response to
changes in shear force acting on the vessel wall, ECs can produce endothelin-1, a vasoconstrictor, or NO,
a vasodilator40. Overall shear stress on ECs aid in maintaining VSMCs in a quiescent state, preventing
neointimal hyperplasia and luminal narrowing. If ECs experience high strain and low levels of oscillatory
shear stress, they begin to secret inflammatory molecules like TGFβ, which promotes the synthetic
proliferative state. It has been suggested that induction of NO by ECs contributes to the negative regulation
of PDGF, a biomolecule that triggers the synthetic phenotype in VSMCs41. Additionally, NO release by
endothelium also inhibits MMP9 induction in VSMCs. MMP-9 is a gelatinase that acts directly on elastin,
a primary structural protein of the vascular ECM, suggesting that shear stress directly affects elastin
remodeling in the presence of both VSMCs and ECs. Investigating the wide variety of responses to
biomechanical cues in vasculature highlights the importance of a dynamic environment to maintaining
proper blood flow. If the cells of a blood vessel have limited ability to respond to such cues, they will
eventually become diseased.

1.3 Available Alternatives
Additional methods for revascularization consist of percutaneous coronary interventions (PCI). In
1977, percutaneous transluminal coronary angioplasty was developed42. This method utilized the inflation
of balloons to widen narrowing vessels, however the procedure was relatively complicated and had a high
9

failure rate. The next generation of PCIs featured stents, small stiff tubular structures inserted into the vessel
lumen and expanded to open the passage. These have evolved from simple bare metal stents to drug eluting
stents, which are functionalized to reduce thrombogenicity and the potential of restenosis43. Stents are now
the preferred treatment method for minor coronary lesions, however the criteria for determining if PCI or
revascularization surgery is necessary requires further elucidation7,43.
Due to the superior patency of autologous vein grafts, researchers started investigating allogenic vein
grafts for patients who lack suitable autologous vessels44,45. Early clinical experience exhibited patency
rates of <50% after 4 years, suggesting un-altered allografts were unsuitable for use as arterial
replacements46. Fixed human umbilical veins (hUV) had experienced some success in animal trials in the
mid 1970’s47–49. The fixative, glutaraldehyde, made the grafts exceptionally resilient to infection and
assisted in retaining their structure in vivo. Unfortunately, the grafts no longer retained their ability to
remodel in vivo, excluding them from use with pediatric patients. Clinical results with commercially
available hUV vascular grafts (Dardik Biograft, Meadox Laboratories, Oakland, NJ) were promising, with
stabilized hUVs demonstrating patency rates nearly comparable to SV interventions in femoral popliteal
bypass (70% after 6 years) and 100% patency after 16 months in coronary artery bypass 50,51. Still,
complications associated with this graft like the fragility of the intima makes the surgical procedure
difficult52.
Decellularized bovine and human cadaver grafts were also extensively researched and made up some
of the first commercially available acellular ETVGs in the 1970s such as Artegraft (North Brunswick, NJ),
Procol (Hancock Jaffe Laboratories Inc., Irvine, CA), and Cryovein (CryoLife, Kennesaw, GA) 53. While
these vessels are approved for use in most revascularization procedures, it is with an understanding that no
autologous candidate is available. In addition to cadaveric grafts, decellularized small intestinal submucosa
(SIS) functionalized with heparin and vascular endothelial growth factor were studied in the vasculature of
lambs. Interestingly, when deployed in neonatal lambs the SIS grafts exhibited increased elastin production
and diameter dilation accommodating for growth, suggesting that this method may hold potential for the
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treatment of congenital heart defects54. Unfortunately, this study was never progressed towards clinical
trials.

1.4 Engineered Tissue Vascular Grafts (ETVGs)
These initial attempts to find small diameter vascular replacements signaled the beginning of a new
era of cardiovascular medicine: the engineered tissue vascular graft. ETVGs are an enigma which promise
to be a manufacturable blood vessel substitute that exhibit all the functional characteristics of native
vasculature. In addition to relieving supply limitations associated with autologous grafts, ETVGs would be
especially ideal for pediatric patients with congenital heart disease who require grafts that grow with them,
eliminating the need for reoccurring invasive surgeries. When planning how to construct an ETVG it is
important to consider the functional requirements of the tissue being replaced. The basic functional
requirements for vascular tissue engineering include non-immunogenicity, sufficient mechanical properties
like burst pressure and fatigue strengths as well as a stable and non-thrombogenic lumen55. From early
research it was evident that the vessel needed sufficient elasticity in order to avoid developing neointimal
hyperplasia at the anastomotic sites. From an end-user perspective, the feasibility of the design must also
be considered. The time and effort needed to create a fully mature ETVG, the ability to maintain sterile
conditions throughout production, the method used to store and transfer the ETVG to the intended recipient,
and the ease with which the scaffold can be manipulated during surgery are all of the utmost importance.
There are a wide variety of methodologies currently employed for the creation of ETVGs which can be
delineated into 4 major categories: synthetic functionalized scaffold approaches, biological matrix
approaches, and cellularized scaffold based approaches56.
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1.4.1 Synthetic Functionalized Scaffolds

Figure 4. Flow chart of the in situ vascular engineering technique. Modified with permission from [56].
In recent years, the trend has been to create “off the shelf” ETVGs from synthetic polymers that
have been functionalized to encourage host cell migration in situ and non-thrombogenic properties57 (Fig
4). While the concept of an acellular ready to use graft seems like the holy grail of vascular tissue
engineering, one major failure in researching this method is acknowledging the mode of healing
experienced at the intended implant site. In humans, transanastomatic endothelial outgrowth is limited to a
few millimeters away from the anastomosis and comes to a complete halt just under a year58. This reveals
that the only available modes of endothelial cell (EC) recruitment in humans are either facilitated fall out
healing or transmural endothelialization, yet the majority of the studies investigating in situ regeneration
12

methods use short graft lengths in animal models that exhibit rapid transanastomatic endothelialization,
which limits the clinical relevance of the studies in question59. Experimental models that exclude
transanastomatic outgrowth as well as both transanastomatic and transmural endothelialization for
examining fall out healing specifically have emerged in the last 40 years, but their use has been limited60,61.
From these studies it can be surmised that transmural endothelialization should be the focus of in situ
vascular engineering efforts going forward, and those studying this method should take extra care to use in
vivo models that give meaningful results.
The in situ approach is also limited by the mechanical properties of the materials the ETVGs are
made from, as the most common driver of failure in current studies is compliance mismatch62. This is
applicable to the stiff polymers typically used for this application, however, it also holds true for in situ
methods featuring fast degrading polymers. In a study by Wei and colleagues testing rapidly degrading cell
free grafts in the rat abdominal aorta, the resulting vasculature was compliant and achieved a patency of
80%63. However, translating to this to higher-pressure systems in large animal models is unfeasible.

1.4.2 Natural Matrices
Completely natural matrices, devoid of synthetic polymers, have been investigated since early
attempts at ETVG development, starting with the decellularized allografts and xenografts attempted in the
early 1970s. One of the earliest attempts was a form of autograft called the autoplastic cutis graft in 1958,
which was made from the graft recipients own skin64,65. Some research groups operate under the assumption
that scaffolds force cells to develop unnaturally rather than facilitating proper alignment. This line of
thinking gave rise to self-assembling ETVGs, where cells placed in a 3-D environment with the right stimuli
organize themselves into complex tissue structures, no scaffold necessary66. Three main strategies have
been investigated, including cell-sheet assembly, micro-tissue aggregation and cell printing (Fig 5).
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Figure 5. Methods for ETVG manufacturing using natural matrices. Copied with permission from [66].
Cell-sheet wrapping has been the most successful, making it all the way to clinical trials as
hemodialysis access grafts, A-V shunts, lower limb revascularization and radial artery replacement67,68. The
main drawback associated with cell sheet wrapping is the manufacturing time of over 30 weeks, which may
be too long for someone in need of vascular bypass. Briefly, autologous cells are harvested from the patient
and cultured until they form fully confluent tissue sheets with well-defined ECM, then they are gently lifted,
wrapped around mandrels, and cultured for an additional 12 weeks while the concentric layers fuse to form
the mature ETVG69. Microtissue aggregation involves culturing cells onto temperature responsive
polymers70. Once the construct is completely confluent, the polymer is signaled and shrinks to release the
formed ETVG. Bioprinting is one of the new methods being outfitted for ETVG manufacturing and offers
more flexibility in terms of the shapes it can create71. Many materials can be utilized in bioprinting, from
polymers to cells encapsulated in various protein based gels72–74. There is also preliminary research being
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done on 4-D bioprinting using smart materials that can respond to environmental cues like temperature or
pH, which opens up countless possibilities for advanced graft functionalization75. Current research is
focused on printability of desired constructs, and more research needs to be done before we can tell if this
method will produce viable ETVGs. Overall, natural matrices are one of the most promising approaches to
ETVG development, but the long incubation periods required to meet mechanical function requirements
still make them a less attractive option than autologous grafting.

1.4.3 Cellularized Scaffolds
Polymeric scaffold-based methods are the most researched and most variable form of ETVG
development. Over the last 30 years many variables have been identified within this methodology including
the materials, cell populations and culturing techniques applied76–78 (Fig 6). They can be divided into two
main categories: permanent and biodegradable. Permanent scaffolds are the easiest to manipulate, yet they
suffer from the same potential issues as acellular grafts when it comes to mechanical property mismatch. It
is easy to achieve the desired burst pressure and fatigue strengths, but this usually comes at the cost of
compliance which leads to intimal hyperplasia formation at the anastomosis79. The synthetic materials also
offer very few cell attachment sites, making it difficult to achieve a fully confluent endothelium, but both
of these issues can be overcome with the appropriate choice of materials, coatings and manufacturing
techniques80.
However, synthetic ETVGs have very little remodeling potential, making them an unattractive
option for pediatric patients. Synthetic permanent ETVGs have achieved clinical success with follow-up
periods of up to 17 years when complemented with a confluent autologous endothelium, but researchers
still admit that autologous grafting is the preferable option in regards to long term patency 81. The lack of
bioactivity in synthetic ETVGs led scientist to consider the addition of natural polymers that are typically
found in the ECM. This provided more cell binding sites and a general improvement in biocompatibility of
manufactured ETVGs82,83. Collagen, gelatin, elastin, fibrin, and silk-fibroin are the most extensively used
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biopolymers in tissue engineering, and can be susceptible to degradation in vivo, which can lead to
aneurysm formation and rupture.

Figure 6. Examples of techniques for manufacturing cellularized scaffolds. Copied with
permission from [66].
Biodegradable scaffolds are the middle ground between scaffold-based approaches and selfassembling ETVGs. Ideally this method would combine the speed and production ease of synthetic grafts
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with the in vivo remodeling potential of natural matrices84,85. Keeping all the usual functional requirements
in mind, biodegradable ETVGs must also consider degradation rate. Essentially, the polymer must degrade
at a rate equal to or slightly slower than the rate of neo-vascularization to ensure that the resulting vessel
maintains functional mechanical properties throughout development. Most of the attempts to investigate
these methods have been isolated, disorganized, and generally unsatisfactory, leading to limited
advancement in the field, but this is also the area that has been researched the most, contributing significant
information for the development of systematic ETVG procedures.

1.4.4 Modes of ETVG Failure
ETVG failure can be classified into 3 categories dependent upon the timespan in which they fail
after implantation. The first category is acute failure which occurs within 3 months after implantation and
is typically attributed to infection and thrombosis12. Infection is a risk associated with any surgery, and risk
mitigation techniques in this context are fairly conserved across surgical procedures. The risk for
thrombosis is typically attributed to a coagulation reaction driven by platelet adhesion to a thrombogenic
lumen80. We know that this can be avoided most readily and consistently avoided by a confluent layer of
non-thrombogenic autologous endothelium, but primary cell isolation and expansion to achieve cell
numbers relevant to ETVG manufacturing is a major detriment to manufacturing time81. In situ engineering
techniques typically employ an anti-thrombogenic molecule coating, such as heparin, however as
previously discussed rapid endothelialization of such grafts after deployment is unlikely. If the coating
wears off before endothelialization occurs, it is likely that thrombosis will develop leading to graft failure.
Midterm failure occurs between 3 month and 2 years after graft deployment and is typically driven
by a compliance mismatch between the implanted graft and native vasculature. The unique mechanical
properties of vasculature are difficult to emulate, and typically when designing ETVGs, compliance is
sacrificed to achieve adequate strength to withstand arterial pressures86. Unfortunately, the stiffness of the
implanted graft induces VSMCs to shift into their synthetic state and proliferate, eventually leading to
neointimal hyperplasia and eventual occlusion of the vessel at the distal anastomosis. The mechanism
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behind the causality is poorly understood, but it has been speculated that the difference in compliance
disrupts blood flow causing a loss of energy due to reflection of the pressure and flow pulse wave as it
encounters the graft and propagates through it87. VSMCs in small diameter arteries facilitate the absorption
of pulsatile energy during vasoconstriction and its subsequent release during vasodilation. This contribution
to blood flow is sorely missed in synthetic vascular grafts, which can diminish the pulsatile energy by 60%
due to their increased stiffness88. Recently, a study was conducted that isolated graft compliance as the
single variable of interest in an ex vivo culture model, and the results strongly support this line of thought89.
Thus, ensuring that graft materials demonstrate compliance values similar to native vasculature is the way
to most readily avoid midterm failure, though several other factors may contribute to intimal hyperplasia
development and graft failure.
Late term failure typically occurs after two years post implantation and involves a return of
atherosclerosis in the effected area12. As previously mentioned, those suffering from CVD will likely need
multiple revascularization surgeries in their lifetime, even if autologous grafts were used in the procedure.
Late term failure can be attributed to deterioration of graft properties or a failure of the graft to fully integrate
with host tissue and undergo remodeling.

1.4.5 Experimental Progress
Over the past 50 years, research in the field of small diameter ETVGs has been broad, but a few
relevant discoveries have been made90. A meta-analysis of ETVG preclinical trials by Skovrind and
coworkers91 has shown that a living cell component in ETVGs typically results in better long term patency
rates when compared to ETVGs without (Figure 7). The same study also recognizes functional coatings of
the scaffold surface as a contributing factor. Both are often used in ETVG development to modulate the
immune response to ETVGs and enhance in vivo integration with host tissue. As such it is assumed that
great care must be taken with ETVG manufacturing to ensure the structure promotes cell seeding,
proliferation and differentiation both in vitro and in vivo, encouraging continuous remodeling after
implantation. According to recently collected data, the EC layer is the most important for achieving early
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patency, but the average follow-up for these studies is only 56 days which is much too short to evaluate
effects on mid to long term patency91. Achieving a healthy and functional media equivalent may yet prove
vital for long term patency of ETVGs. Improved mechanical properties can be achieved by careful selection
of materials and manufacturing techniques, but another method of achieving stronger tissues with enhanced
compliance is preconditioning cellularized ETVGs in a bioreactor with the capability to apply mechanical
strain. When analyzed as a factor in ETVG development, Skovrind also found bioreactor preconditioning
to improve patency of implanted ETVGs (Fig 7). Given that the primary effect of conditioning is to enhance
ECM production by VSMCs, this also suggests the VSMC component is essential for promoting ETVG
patency.

Figure 7. Select variables considered in ETVG development and their effect on graft patency. Dotted lines
indicate standard error. As the length of ETVGs increase, their patency levels tend to decrease. By
modifying scaffolds with conjugated molecules, seeding them with cells, and preconditioning assembled
ETVGs in a bioreactor, graft patency improves significantly. Modified with permission from [91].
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1.4.6 Seeding Techniques
The small diameter tubular geometry of ETVGs makes it difficult to efficiently deliver cells onto
the luminal surface evenly. Optimizing seeding efficiency by promoting rapid cell attachment to the
scaffold and mimicking tissue microstructure may contribute to relieving current constraints related to cell
availability, prolonged culture protocols and mechanical and physiological performance92. Many seeding
methods have been utilized in ETVG development. The first and most employed is drip seeding, in which
cell suspension is deposited directly onto the scaffold material93–96. This is usually done along the outside
of the scaffold as pipetting into the scaffold lumen can prove difficult and even cell seeding is not likely to
be achieved. Other seeding techniques that have been investigated include magnetic cell labeling97–99,
rotational seeding100–102, and perfusion based seeding103–106. In addition to seeding ETVGs, perfusion based
cell seeding has been investigated in many applications such as tissue engineered bone grafts107,108, heart
valves109, and other scaffolds of unique geometries110. Perfusion cell seeding has consistently been shown
to improve cell adhesion to surfaces, increase cell proliferation, and encourage uniform cell distribution.
Perfusion based cell seeding is typically bioreactor mediated, requiring a continuous or oscillating flow to
facilitate the attachment of cells to the desired scaffold. In addition to being used as a seeding mechanism,
bioreactors are often used to facilitate graft conditioning before implantation to enhance mechanical
properties.

1.4.7 Mechanical Conditioning and Bioreactors
Mechanical conditioning is widely recognized as one of the most relevant methods to enhance
tissue accretion and microstructure in engineered tissues. In most bioreactor conditioning models; uniaxial
circumferential pressure is applied to mimic pulsatile conditions of the vascular system. Though these
experiments have been largely disorganized, very rarely revealing relevant trends for manipulation, the
universal effects of mechanical stimulation on ETVGs are apparent. Cyclic strain generally leads to
increased cell numbers, higher collagen content, higher yield and ultimate stresses, higher elastic modulus,
higher burst pressures and higher suture retention rates111–113.
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Niklason and colleagues pioneered the inclusion of cyclic circumferential stretch in ETVG
development in the late 1990s. Cyclic distension was applied to cell seeded PGA scaffolds via a silicone
catheter for a period of 8 weeks (Fig 8 A). The dynamic environment led to increased collagen production
and superior mechanical properties such as higher suture retention rates, higher burst pressures, and higher
strength. Niklason and colleagues further investigated biaxial stretching in 2016114 (Fig 8 B). The same
benefits gained from uniaxial stretch were present, but other more unique effects were also observed. While
elastin deposition has been variable when investigating the effects of mechanical stimulation on ETVG
development, biaxial stretching increased the level of elastin fiber maturation as well as increased fibrillin1 formation and collagen III formation and undulation. This organization is similar to that seen in native
vasculature, which had not been achieved via uniaxial stretch. This organization was most likely what
contributed to the improved mechanical properties in biaxially treated grafts like increased distensibility
and compliance. The effects this improved microstructure has on in vivo performance has not been
investigated.
Though the list of studies utilizing circumferential strain in their procedure is lengthy, few truly
sought to elucidate the role mechanical conditioning plays in ETVG development, and studies incorporating
axial conditioning are extremely rare. In 2011, Tranquillo and coworkers published results regarding cyclic
distension applied to fibrin gel grafts and effect on mechanical properties115 (Fig 8 C). Over the course of
the dynamic culture period the ETVG was allowed to naturally contract in response to the conditioning.
The study found that mechanical conditioning encouraged the development of mature elastin fibers and
enhanced mechanical properties. Additionally, ETVGs typically experienced an axial retraction of 60% and
had a significant effect on collagen fiber alignment when compared to fixed end controls. Determining
optimal conditioning protocols for ETVGs has been rather empirical, and progress has been slow without
relevant in vivo models for confirmation of improvement. Though the role of biomechanics in regulating
non-thrombogenicity, vasoactivity, ECM synthesis and regular maintenance is well established, harnessing
these pathways to create ETVGs with targeted properties has not been sufficiently investigated. A
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comprehensive perspective looking at the effects different levels of mechanical stimulation influence at the
cellular level, in engineered tissues and in vivo could reveal the major modes of mechanical based
remodeling and how best to manipulate them.

Figure 8. Examples of bioreactors capable of applying mechanical strain to cultured ETVGs. A) illustrates
the pulsatile bioreactor developed by Niklason and coworkers. The pulsatile pump creates circumferential
distension via PBS flow through balloons in the graft lumen. Copied with permission from [93]. B) depicts
the biaxial stimulation bioreactor created by the Niklason group, modified from A with a linear motor to
facilitate axial stretch for one of the cultured ETVGS. Copied with permission from [113] . C) is a schematic
diagram of the pulsatile bioreactor created by Tranquillo. The syringe is mounted to a reciprocating pump
which consistently pulses flow into the upper manifold, facilitating medium flow through the
lumantransmurally through the tissue and through the lumens collecting on the ablumenal side of the grafts
and reinjected into the upper manifold. Copied with permission from [115].

1.4.8 Limited Clinical Progress
Very few ETVGs have progressed all the way to clinical trials, despite over 50 years of dedicated
research in the field. Major considerations to take into account include the consistency of the manufactured
22

product, the simplicity of employing the device, the suitability of the animal models employed for in vivo
testing, the design of the preclinical proof of concept studies, and adequate safety testing. However, these
benchmarks are not specified in the case of ETVGs and the level and quality of in vivo testing varies widely
between studies. It has been found that the majority of in vivo studies evaluate graft performance of the
course of 6 months, but many studies only evaluate performance for a month or less 91. These time periods
are not long enough to be clinically relevant, as neointimal hyperplasia can take up to 2 years to develop.
Early on, attempts at improving that patency on ePTFE grafts in femoral popliteal bypass applications
was carried out by Zilla and colleagues81. A large-scale clinical study was conducted on the effects of seeded
a autologous EC monolayer into ePTFE conduits affected graft patency in vivo. The study characterized
improved methods for endothelial cell isolation and proliferation for and the positive effects on graft
patency were significant. The first attempt at human utilization of a fully biological vascular graft was
attempted by L’Heureux and colleagues through the company Cytograft Tissue Engineering68. These grafts
were cultured from allogenic donor fibroblasts as previously described, and the culture process took
approximately 7 months. Three of these grafts have been implanted in patients as arteriovenous
hemodialysis access shunts with positive results, however the length of time required for manufacturing
ultimately lead to the company abandoning this method116. Another graft was developed by Shinoka, Bruer
and coworkers using a 50:50 blend of PLCL and either PLA or PGA statically seeded with autologous bone
marrow-derived mononuclear cells117. Scaffolds were implanted as large diameter pediatric vascular grafts.
The study found that 11 years after implantation patients exhibited no graft related complications and the
original graft material completely degraded in that time frame118. This study holds particular significance
due to the simplicity of the procedure. Mononuclear cells isolated from the patient’s bone marrow are
isolated and manually drip seeded onto porous PGA scaffolds merely 2 hours before implantation. This
may be attributed to the youth of his subjects if we remember the increased elastin content seen in the
rapidly degrading ETVGs implanted in neonatal lambs, however more data is needed before a theory can
be determined.
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Currently, Niklason and colleagues at Humacyte are conducting clinical trials with their human
acellular vessel (HAV)119. The HAV is constructed by seeding donor smooth muscle cells onto a PGA mesh
scaffold. The seeded scaffold is conditioned in a bioreactor 8 weeks to develop de novo tissue structure,
and subsequently decellularized before implantation. The HAV is currently in Phase III trials for use in
vascular trauma and arteriovenous hemodialysis access and is in phase II trials for use as treatment of
peripheral artery disease.

1.5 Objectives
Progress in the ETVG paradigm requires a systematic approach to reach better mechanistic
understanding of the cause-effect interplay between implant properties, host reactions, and their modulation
with controllable parameters. There are a vast array of variables that are associated with ETVG development
such as implant material, manufacturing techniques, scaffold functionalization, cellularization, types of
cells utilized, seeding method, preconditioning with a bioreactor and method of bioreactor stimulation.
However, it is finally becoming clear which variables hold the most influence in terms of graft patency.
The development of a dynamic bioreactor environment and automated cell seeding apparatus will enhance
the creation of cellularized biodegradable vascular grafts with increased patency rates.
This dissertation documents the development of methods for the systematic high throughput
investigation of the effects mechanical conditioning exert on engineered tissue vascular grafts designed for
use in a rat aortic interposition model. The main objective can be split into 3 aims:
(1) To design and manufacture a seed and culture bioreactor system for the cultivation of ETVGs with the
capacity to apply biaxial mechanical stimulation.
(2) To fully evaluate the seeding capabilities of the bioreactor system for consistency between samples.
(3) To develop a pipeline to study the effects of mechanical conditioning on ETVG composition,
microstructure, mechanical properties and patency.
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In Chapter 2, we develop the animal model used to evaluate the in vivo response to implanted
ETVGs. This is a significant step, as the in vivo model directly dictates the target graft size and surgical
techniques used. In Chapter 3, we refine our initial bioreactor design and conduct extensive testing on the
seeding capabilities of the system, ensuring consistency between samples at culture time t = 0. This is
important because it is a confirmation of limited variability between ETVGs, increasing the statistical
relevance of results. In Chapter 4, we fully define the mechanical culture capabilities of the bioreactor
design and methods used to determine the mechanical properties of the developing ETVGs. Chapter 5
provides a brief summary of our accomplishments and outlines future experiments using the system for its
intended purpose.
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2 Chapter 2

Static Culture in vitro and in vivo deployment in rats

There are a wide variety of variables associated with the manufacturing of ETVGs. Keeping the desired
end goal in mind when considering ETVG production is essential to make informed choices. The goal of
this work was ultimately to examine the effects of mechanical stimulation on ETVG development as well
as the host response following implantation. Of the methods mentioned above, cellularized scaffolds is the
most conducive towards the study of developing tissue in vitro. Acellular methods utilize scaffold
functionalization to encourage the migration of host cells onto the graft in situ, which is fundamentally
different in technique and not relevant to this project. While natural matrices and gels commonly employ
mechanical conditioning to achieve the required physiological strength, the timeline of such development
is also out of the scope of this project’s goals. We determined that seeding porous scaffolds would be the
quickest way to assemble a rough ETVG template that could withstand mechanical strain for conditioning
and implantation in an animal model.
For our in vivo study, we wanted to evaluate our grafts as small diameter vascular grafts (< 5 mm) and
cost effectiveness was critical. Commonly used models for cardiovascular research include mice, rats,
rabbits, pigs, sheep, dogs and baboons120–124. Large animal studies with pigs, sheep, and baboons are
excellent for clinical translation research, however the cost associated with keeping them is high. The
presented study is a proof-of-concept approach, so small animal models were chosen as the most
appropriate. The aortic interposition model in rats is commonly used to study ETVGs in vivo. The vessel
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is approximately 2 – 3 mm in diameter and grafts sections used in this model are typically 1.5 cm in
length125–128.
To facilitate the development of de novo tissue with remodeling capability, we used a biodegradable
polymer to construct the scaffold. Options included linear α-hydroxy esters such as poly(lactic acid) (PLA),
poly(glycolic acid) (PGA), and poly(ε-caprolactone), (PCL)), elastomeric segmented polyurethanes (PU),
and highly crosslinked polyesters (e.g., poly(glycerol sebacate) (PGS)). PLA, PGA and PGS all degrade
over the course of a couple weeks in physiological conditions making them ideal for applications were rapid
degradation is encouraged124,129,130. PU is a highly compliant material which is advantageous for avoiding
problem related to compliance mismatch in vivo131. The properties of PU are also highly tunable making it
a popular choice for those studying the effects of graft properties on cell behavior. PCL is FDA approved
for use in medical devices and has a much longer degradation period compared to other biodegradable
polymers; 2 years rather than 2 weeks132. By blending de novo tissue with a structurally supportive polymer,
the overlap of tissue development and scaffold degradation is extended and opportunities for process
optimization multiplied. Methods for manufacturing polymer based scaffolds are to numerous to be listed,
but one of the most well studied and consistently used in cardiovascular applications is electrospinning 133–
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. The mechanical and biological properties of electrospun vascular grafts can readily be tailored by

altering the composition and combination of the blended polymers or copolymers. The structural properties,
such as polymer fiber size and scaffold thickness, can be controlled by adjusting electrospinning settings
(voltage, speed, time, and concentration of the polymer solutions)85.
Cell types used in vascular tissue engineering are typically vascular endothelial cells, vascular smooth
muscle cells, or stem cells. To avoid an immunological response after implantation, ETVG development
methods typically aim to use autologous cell sources. While the benefits of having a fully confluent layer
of autologous endothelium are well known, harvesting enough cells for use is a major problem in the field.
This problem can be alleviated by using stems cells, which can either be harvested 136 or induced from a
different population of host cells such as dermal fibroblasts126. However, directing the differentiation of
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stem cells in vivo can be challenging, and maintaining the differentiated state is inconsistent. While
studying the use of both types of cells in ETVG applications is essential towards advancing the field, neither
are truly relevant in the context of this study. The primary provider of mechanical support in vasculature is
the VSMC, due to its contractile ability and SEM secretion. By using an immortalized VSMC line we avoid
the complication of having to isolate cells from target tissue or having monitor the differentiation of stem
cells while still being able to study relevant cell behavior in response to stimuli.
In this section, we review the development of our tissue engineered vascular graft model and initial
bioreactor design concept. Methods regarding scaffold materials and manufacturing techniques,
postprocessing, seeding methods and bioreactor design will be explained, preliminary analysis techniques
for ETVGs optimized, and initial results discussed.

2.1 Methods
2.1.1 Scaffold fabrication
Polycaprolactone (PCL; Mn = 80,000), N,N-Dimethylformamide (DMF) and Tetrahydrofuran
(THF) at high performance liquid chromatography grade were obtained from Sigma-Aldrich (St. Louis,
MO) and used without further purification. The 14 wt% polymer solution was prepared by dissolving PCL
in a solution of THF and DMF with a weight/weight ratio of 1:1 and stirred for 24 hours at 40℃. The
solution was observed to be clear and without trapped air before every use.
The mandrel used to collect the PCL fibers and form the scaffold is a stainless-steel rod 2mm in
diameter. An aluminum foil strip, 1cm thick and 13 cm long, is wrapped around the mandrel tightly. The
wrapped mandrel is then mounted between of lathe chucks designed to suspend the mandrel in the
electrospinning system. The aluminum wrap is essential for scaffold removal from the mandrel once the
spin is complete. The PCL solution is extruded from a 1 ml syringe with a 26-gauge stainless steel blunt tip
needle and a mass flow rate of 1.2 ml/h. The mandrel is mounted 20 cm away from the needle on a stage
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set to translate 5 cm continuously at 1 cm/s as the mandrel rotates at 720 rpm. A high voltage (15 kV) was
applied to the base of the needle for 40 min to facilitate fiber collection.

Figure 9. Representative images obtained from SEM imaging at A) 20x, B) 300x and C) 3000x
magnification. High magnification images were binarized for further analysis using ImageJ software (D).
When the spin is completed, the aluminum sheet is removed from the mandrel and cut to size
depending on its intended function. Samples are dried overnight in the presence of the blue rocks to
evaporate any remaining solvent and a small section of the scaffold is excised for SEM imaging. Sections
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were imaged at 5x, 500x and 3000x at random spatial intervals (Fig 9). 3000x was the optimal magnification
for high resolution imaging and analysis of scaffold microstructural properties based on pixel size in relation
to fiber diameter.

2.1.2 Scaffold Characterization
2.1.2.1

Mass Distribution
Each spin produced a 12cm long tube of electrospun PCL material. the last centimeter of material

on either end was removed and the remaining 10 centimeters used for analysis. The scaffold was cut into 1
cm sections and each section labeled 1-10 in longitudinal order. Section mass was reported as the average
of 3 mass measurements taken with a scale. The exact length of each section was measured x3 with calipers
and average for the final reported value. Thickness was determined by spreading the scaffold section
between two glass coverslips and measuring the thickness with a micrometer. This value was subtracted
from the thickness of the coverslips alone and reported.
2.1.2.2

ImageJ Analysis
SEM images of scaffold microstructure were taken at random spatial intervals across the 10 cm

length. Scaffold sections were mounted to carbon taped covered pegs with their luminal surface facing out.
The scaffold sections were imaged using SEM at 20x and 300x for qualitative analysis, but 3 addition
images were acquired at 3000x for quantitative analysis using an ImageJ software called DiameterJ137.
DiameterJ utilizes a variety of algorithms to binarize the images such that the first 3-4 layers of fibers are
white and everything else is black. The selected binary images are then used to quantify average fiber
diameter, fiber orientation and pore size for that sample in relevant units given a pixelated length of the
scale bar.
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2.1.2.3

Uniaxial Mechanical Testing

Figure 10. The uniaxial mechanical tester for scaffold material characterization. The scaffold section is
fastened to 6 metal hooks (top left) and mounted between two custom fabricated brackets designed to evenly
distribute force between the hooks (top right). One bracket is attached to a load cell, while the other is
connected to a linear actuator. The camera tracks the movement of 4 dots on the scaffold surface to calculate
relative strain. Strain and force measurements from the load cell are saved to a previously indicated file
path. The lab view control window is used to dictate testing protocol and manipulate tracking parameters
for more precise measurements (bottom).
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Scaffold sections 2.5 cm long where mounted via six metal fasteners into the uniaxial testing system
(Fig 10). The hooks were connected via fishing line to brackets outfitted to homogenously distribute force
along the three points of contact with the material edge. The scaffold surface was marked with 4 dots
arrange in a square. A camera was programmed through LabVIEW to track the movement of the four dots,
facilitating the calculation of the scaffold material strain (Fig 10). The force applied to the scaffold material
was measured via a load cell situated on the distal bracket post. Axial tension was applied with an actuator.
Once the scaffold material is mounted appropriately into the system, a pretension of 2 N is applied
and the load cell tared. The material is then prestretched 10 times in quick succession by 1 mm. Once the
scaffold is preconditioned this way, the scaffold is subjected to mechanical tests as dictated by the
LabVIEW program. Controllable parameters in the LabVIEW program include stretch amplitude of the
actuator, stretch period and number of stretch cycles from 1 to infinite. Our sample test protocol utilized a
5%, 8% and 10% stretch level over a period of 30 seconds to determine the elastic modulus. Mechanical
properties after degradation have also been evaluated by subjecting scaffold material to NaOH solutions of
varying PH before mechanical testing.

2.1.3 Vascular Smooth Muscle Cell Culture
Murine vascular smooth muscle SV40LT-SMC cells (VSMCs) (ATCC; Manassas, VA, USA) were
cultured full growth medium containing Dulbecco Modified Eagle’s Medium (DMEM), 10% fetal bovine
serum (FBS) and 200 mcg/mL geneticin (G418), all produced by Gibco. Cells were lifted for passage using
0.025% trypsin solution, At passage 6, cells were harvested for seeding.

2.1.4 Bioreactor Design
The first iteration of our bioreactor cultured 4 scaffolds vertically in a polypropylene jar, and all
four scaffolds were fed from the same media reservoir. Scaffolds were mounted by suture over tubing
connectors, fit snugly into a bracket made of 2 stainless steel washers connected via 2 threaded stainlesssteel rods. The bracket structure was attached to the jar lid via the stainless-steel rods as well. The lid
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contained 9 holes: 2 for the stainless-steel rods, 4 for the individual tubes that feed the proximal scaffold
ends, 2 for the drainage tubes that cycle the media from the bioreactor jar to the reservoir, and 1for the filter
that allowed for sterile air exchange (Fig 11). Circulation of culture media was facilitated via peristatic
pumps. To control the fluid level in the bioreactor jar, the pump hosting the tubes that drained the bioreactor
into the reservoirs was set to a speed of 10 RPM while the ETVG feeder tube pump was set to 5 RPM.
Drainage tubing only went 1 inch into the bioreactor jar, well above the proximal end of the scaffold,
ensuring the level of media never dipped enough to expose the scaffold to air.

Figure 11. ETM3 Bioreactor Version 1, for static culture. A) Schematic diagram of bioreactor flow loop,
featuring 2 bioreactor draining tubes and a liquid level control sensor. Should media touch the sensor, the
pinch valve is programed to open, facilitating an increased drainage rate from the bioreactor chamber. B)
the bioreactor chamber components are localized to the lid to enhance ease of handling. When changing
media or manipulating the ETVGS the bioreactor lid could be held suspended in the air, allowing for the
use of both hands for the procedure and limiting contact with possible contaminating surfaces.
Scaffold seeding was conducted via forced transmural flow due to a plug located at the distal end
of the scaffold material. Briefly, approximately 8 million cells were suspended in 50 ml of solution. The
cell suspension was deposited into the media reservoir and the peristatic pump set to 30 RPM to drive the
cell suspension through the connective tubing and transmurally through the scaffold walls. After completion
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of seeding, the plug was removed from the distal end of each scaffold, allowing media to move through the
lumen of the scaffold unimpeded. Media was switched on a weekly basis by removing the media from the
bioreactor chamber, filling the cell media reservoir with 250 ml of fresh culture medium, and resuming
flow to allow the refill of media in the bioreactor system. ETVGs for initial analysis were cultured for 1-2
weeks in this system.

2.1.5 In vivo Studies

Figure 12. In vivo rat model. A) schematic of the surgical deployment of an ETVG as an infra-renal aortic
interposition graft. B) native rat aorta before excision. C) an ETVG immediately following suture to the
native aorta. D) the same ETVG at explant after 2 weeks of in vivo deployment.
Following culture periods of 1-2 weeks, ETVGs were harvested from the bioreactor and place into
ice cold phosphate buffered saline (PBS) for transport to the surgical site. All experimental animals were
treated in accordance with institutional guidelines and the Guide for the Care and Use of Laboratory
Animals, published by the National Institutes of Health (NIH Publication No. 86-23, revised 2011). Select
samples were implanted as aortic grafts in Sprague-Dawley rats through bisection of the abdominal aorta
above the renal bifurcation, a well described aortic interposition by-pass graft in rats78,138 (Fig 12).
Isoflurane (3%) was used as general anesthesia. Anesthesia depth was monitored by checking for the
absence of pedal reflexes. The recipient rat was then placed supine on a warming pad on the operative field
with sodium heparin given intravenously. A long midline abdominal incision was made and the intestine
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retracted outside the abdomen using a gauze to expose the infra- renal abdominal aorta and the inferior vena
cava. The aorta was carefully cleaned and isolated and a proximal and a distal control of the vessel obtained
with vascular clamps. A 1.5 cm portion of the abdominal aorta was then excised with micro-scissors to
match the length of the vascular grafts. The anastomosis of the recipient's abdominal aorta to vascular graft
was completed with continuing 8-0 monofilament suture. After completion of the anastomosis, the distal
clamp was removed to assess for bleeding and then the proximal clamp was removed. The intestines were
returned to the abdomen, which was then closed with 4-0 continuous sutures. The recipient rat was placed
on a warm area, treated with painkillers and allowed to recover. The rats were observed in the surgical suite
until fully recovered from anesthesia and then returned to the housing area. Buprenorphine and cefuroxime
were administered subcutaneously for the first 3 days after surgery, and anti-aggregation therapy started
after surgery with aspirin and dypiridamole.
At the scheduled explant time point, animals were be anesthetized with 3.0% isoflurane inhalation
with oxygen followed by 1 mL of hyper-potassium chloride (2 mEq/mL) cardiac arrest solution intravenous
injection to obtain rapid cardiac arrest at the diastolic phase without additional pain. This method is within
the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association.

2.1.6 Histology Analysis
ETVGs cultured in vivo were stain with H&E and picrosirius en bloc and embedded in OCT
Compound (Electron Microscopy Sciences; Hatfield, PA, USA) to cut 8 μm-thick cross-sections with a
cryotome. Samples harvest from in vivo were immediately embedded in OCT freezing medium and
cryosectioned. Samples were subsequently stained with H&E and Picrosirius red for analyzing the
developing tissue structure. Stained cross sections were imaged with an Eclipse LV100D microscope
(Nikon Instruments; Melville, NY, USA)

35

2.2 Results
2.2.1 Scaffold Morphology

Figure 13. Virgin Scaffold Analysis. Graphs depicting gradient of mass/length measurements and thickness
of unprocessed 10 cm scaffolds. Reveal a restricted area of homogenous properties common to most
manufactured scaffolds (left, outlined in blue). SEM images were analyzed to determine the orientation of
individual fibers in the graft material. The resulting graph reveals that fibers are randomly oriented with no
more than 3% of fibers aligned in one direction. 0o associates with fibers aligning in the circumferential
direction while 90o associates fibers aligned in the axial direction. SEM analysis also revealed the average
fiber diameter and pore size of electrospun fibers. Material stiffness was determined with the uniaxial
mechanical tester. These results are reported at the bottom right.
An appropriate section of homogeneous and reproducible scaffold properties was identified from
the gross 10 cm produced with each spin (Fig 13). This section produces scaffolds 4cm long, 2mm inner
diameter, ~150-200 µm thick with a mass ratio of ~.36-.41 mg/mm. We repeat this process every 10
scaffolds we make to monitor for any changes and preserve our current scaffold quality. SEM analysis of
our scaffold material shows an average fiber diameter of 0.84 µm and an average pore area of 3.33 µm2
(Fig 13). Scaffolds present linear elastic behavior under 10% axial strain with a Young’s modulus of
207±22kPa. Static and dynamic degradation experiments have revealed that no significant changes in mass
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or microstructure occur over a 4-week period under physiologic pH and temperature, clearing them for use
in our experiments (Fig 14).

Figure 14. Mechanical testing analysis. A plot of force vs strain in the x direction is obtained to determine
the young’s modulus from the linear portion of the plot (top). The young’s modulus of 3 sequential tests
are averaged to obtain the experimental modulus. Further evaluation of scaffold properties in terms of
degradation rate is being conducted by evaluating the stiffness of the material after being subjected to cyclic
stretch in a NaOH of pH 12.5, however statistically viable data has yet to be produced. Initial results are
shown (bottom).

37

2.2.2 In vitro Development

Figure 15. Histology of ETVGs after in vitro culture. In our static bioreactor we successfully seeded and
cultured cells for up to 2 weeks. The cells grew in random layers (H&E) and deposited collagen in an
unorganized manner (Picrosirius). Two weeks of culture appeared to result in thicker cell layers and
increased collagen deposition. Scaffold lumen is show with arrows, scaffold thickness highlighted by bars.
Cells located on the external side of picrosirius stained sections are blood cells from contact with the blood
of the intended graft recipient during implantation, graft sections were cut to size at the implant site and
excess used for histology.
Culture methods were confirmed to be successful qualitatively, resulting in full even
circumferential coverage after one week of incubation in the system (Fig 15). Cells appeared to remain
viable and continued to proliferate and deposit ECM over 2 weeks of in vitro incubation according to
histological analysis. Comparison between the two time points suggest that collagen content was increased
significantly, but organization appeared to be random, consistent with results of other studies.
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2.2.3 In vivo Response

Figure 16. Histology of ETVGs after in vivo deployment. Acellular grafts without modification and ETVGs
after one week of culture were compared 2 weeks after implantation. Scaffold lumen is show with arrows,
scaffold thickness highlighted by bars. Both grafts exhibited heavy infiltration of cells into the graft
material. Scaffolds with a cellular component demonstrated massive fibrotic tissue deposition around the
scaffold edge, clearly visible to the naked eye at explant.
Scaffolds cultured for 1 and 2 weeks under static conditions were implanted in successfully SpragueDawley rats. Our survival rate was approximately 60% among subjects that did not die due to surgical
complications. Qualitative observation showed the expected signs of inflammatory response consisting of
fibrous tissue accumulation around the scaffold and thrombus formation within, usually at the proximal
anastomosis. Histology further shows that the thickness of the fibrotic tissue varies between the in vitro
time points (Fig 16).
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PCL scaffolds exhibit degradation of microstructure over time both in vitro and in vivo with the
most extensive being after 2 weeks in vitro and 2 weeks in vivo consistently throughout samples. The 2:2
samples also exhibited increased infiltration of cells into the scaffold material from the outer edge

2.3 Discussion
The methods available for the construction of tissue engineered vascular grafts are numerous and
have been met with varying levels of success. It is well established that scaffold functionalization is a
critical factor in promoting cell adhesion and tissue development in polymer scaffolds. However, the
relative success of different functional molecules and functionalization methods used in the field have not
revealed a superior method. While enhanced results may have been achieved if a functional element was
included during scaffold processing, by simplifying the model we reduce the level of variability affecting
results. The ultimate intention is to characterize the effect mechanical strain has on 3D de novo tissue
development, which can be affected a great deal by the protein composition of the cell’s environment139,140.
The wide variety of functionalization techniques can be translated into an opportunity for functionalization
tailored to produce a specific development outcome when used in tandem with mechanical stimulation
techniques. However, to study the effects of functionalization, a non-functionalized base line must be
established.
The first version of the bioreactor was a positive first attempt that revealed many opportunities for
improvement. A major area that required optimization was the seeding method, which, though very simple,
fostered a high degree of variability between samples. The channels of the peristaltic pump do not facilitate
a fine degree of control over flowrate in the circuit. By depositing the total cell load required for seeding
all four scaffolds collectively in the media reservoir, there was no way to confirm homogenous delivery
between samples. Additionally, variable levels of pressure developed within the ETVG lumen led to the
occasional blowout of the distal end of the ETVG from its tubing connector mount. The consistency of this
occurrence also highlighted the need for a better ETVG mounting system that gripped the scaffold better if
mechanical stimulation was ever applied. Axial mechanical stimulation would also be difficult to apply
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vertically because a vertical stage would need to be designed to house the required components. Finally,
the positioning of the micro-porous filters affixed to the bioreactor lids lead to a buildup of condensation
in the filter material and ultimately contamination of the bioreactor environment when subjected to long
term culture.
Methods of ETVG analysis had to be optimized according to the limitations incurred by our choice
of scaffold material. The melting point of PCL is 60, which is the temperature paraffin wax is heated to
when embedding tissue sections for histological analysis. This prompted the choice of cryosectioning for
structural tissue analysis for the experiments. PCL is also a hydrophobic material, making adherence to
microscope slides after sectioning tenuous when there is minimal tissue present in the sample. As such,
samples developed in vitro were stained en bloc prior to cryosectioning to minimize the number of washes
that needed to be applied to scaffold cross sections after they had been adhered to the microscope slide. We
attempted to use the Fastin elastin assay and Syrcol collagen assay by Biocolor to determine the level of
elastin and collagen deposition at each of the time points, however levels were too low to be detected. This
is unsurprising, as other studies site periods of up to 8 weeks to achieve significant tissue development. The
study would have been strengthened with the addition of a viability test to confirm cells are healthy and
continuously proliferating between time points.
Initially, the scaffolds were intended to be used as interposition grafts in the rate abdominal aorta,
however the diameter of the ETVG and the diameter of the target vessel were significantly different, leading
to improper suturing and surgical failure. By suturing the grafts into the side of the vessel wall, the diameter
of the incision can be manipulated, and the graft can be sutured appropriately. This study lacks true clinical
relevance since the length of the graft is not sufficient to emulate human CABG condition. However,
endothelialization of the graft lumen is not the focus of this research, the host reaction to graft mechanical
properties is. As such, the consideration is irrelevant for this level of study. When comparing samples
developed in vitro to their counterparts employed in vivo, it is apparent that no further development of the
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VSMC layer occurs after implantation. However, there is heavy recruitment of cells on the adventitial
surface that can most likely be attributed to macrophage recruitment in response to vascular injury.
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3 Chapter 3

Characterization of seeding efficiency of bioreactor V2

This section is an abridged version of the publication Saunders et al. Evaluation of perfusion-driven cell
seeding of small diameter engineered tissue vascular grafts with a custom-designed seed-and-culture
bioreactor. PLoS ONE 2022
The method of cell seeding onto any scaffold determines the number of cells initially present for in
vitro culture and their spatial distribution, which in turn dictates the proliferation, migration, and phenotype
of cells as neo-tissue develops141. Achieving an even distribution of viable cells can prove challenging as
the methods currently utilized are inherently inconsistent. Various techniques have been investigated to
seed small diameter tubular scaffolds due to the unique problems associated with this class of geometries
142

. The most widely employed is dripping cell suspension onto the scaffold surface. However, this method

is unreliable due to the manual nature of the procedure, and user independent consistency is challenging to
achieve 143. Various uncommon and less well-established cell seeding techniques that aim to use specific
directing forces to control the seeding outcomes of the constructs are too hampered by the complexity of
devices and procedures to be considered for regular use. Perfusion-based cell seeding, also called vacuum
cell seeding or filtration cell seeding, has been employed in many applications such as seeding bone grafts,
vascular grafts, heart valves, and other scaffolds of unique geometries. Perfusion based seeding has
consistently been shown to improve cell adhesion to surfaces, increase proliferation, and encourage uniform
cell distribution compared to traditional static methods110,144.
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Herein, we investigate perfusion seeding as a preferred method for luminal seeding of scaffolds
with tubular geometries and quantify the performance of a custom-built perfusion seed-and-culture
bioreactor against static seeding methods of cell delivery regarding spatial distribution of seeded cells and
their viability. The seed-and-culture bioreactor design was developed as a controlled environment capable
of seeding and culturing 4 ETVGs simultaneously under identical conditions. Using the bioreactor system,
a variety of environmental stimuli including dual axial mechanical stimulation and the addition of
environmental growth factors may be administered to the developing ETVGs semi automatically with
minimal handling. Having multiple directly comparable data points is essential to increasing the speed at
which research may be conducted but scaling up these experimental processes can be difficult. We suggest
bioreactor-mediated perfusion seeding as a simple method that can be easily and reproducibly applied to 4
scaffolds concurrently in a bioreactor environment. Furthermore, the automatic process reduces variability
in the seeding method, further reducing variability in ETVG quality between samples.

3.1 Methods
3.1.1 Seeding experiment.
Murine vascular smooth muscle SV40LT-SMC cells (VSMCs) (ATCC; Manassas, VA, USA) were
cultured as previously described. Prior to seeding, all scaffolds were prewetted with full growth medium
overnight. During and after seeding, scaffolds were maintained in a 5% CO2 incubator at 37 ºC. Twentyfour hours after seeding, scaffolds were collected for analysis. Harvested scaffolds were split into 5 equal
sections approximately 6 mm long for analysis of seeding efficiency across the full length (Fig 17D).
Section 1 represents the upstream entry, whereas section 5 is the distal end of the scaffold.
Seeding took place in three distinct methods: 1) bioreactor-mediated perfusion seeding, 2) static
injection counterpart seeding, and 3) drip seeding (Fig 17 A-C).
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Figure 17. Seeding methodology. Seeding method diagrams for (A) the bioreactor mediated perfusion
seeding method, (B) static injection counterpart seeding method and (C) drip seeding. (D) Operating
principle of bioreactor mediated perfusion seeding method. Numbers indicate sample organization for
analysis.

3.1.1.1

Bioreactor-mediated perfusion (BMP) seeding
Four scaffolds at the time were mounted into the custom-designed seed-and-culture bioreactor (Fig

17 A). The design of the bioreactor chamber is fully described in Chapter 4. 10 mL of cell suspension,
containing 2 x 106 VSMCs, was drawn into sterile syringes and connected to the flow loop upstream of
each scaffold. The tubing at the downstream end of each scaffold was clamped shut and the cell suspension
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was driven through the porous scaffold (Fig 17 D) at a rate of 10 ml/hr with a syringe pump (New Era Pump
Systems; Farmingdale, NY, USA).
3.1.1.2

Static injection counterpart (SIC) seeding
Scaffolds were mounted onto modified stainless steel cannulas and filled with 100 ul of

concentrated cell suspension containing approximately 2 x 106 VSMCs (Fig 17 B). Each end of the
construct was closed, and the scaffold submerged in full growth medium. This method replicated all the
conditions of the perfusion-driven seeding method except the transmural pressure gradient supplied by the
syringe pump.
3.1.1.3

Drip seeding
Using standard aseptic procedures, 80 µl of a concentrated cell suspension containing

approximately 2 x 106 VSMCs was carefully pipetted directly onto the luminal surface of the tubular
scaffolds (Fig 17 C). Seeded scaffolds were placed in individual 100 mm culture dishes and incubated for
1 hour at 37°C. During this period the scaffold was rotated every 15 min to encourage even cell distribution.
After one hour, scaffolds were submerged in full growth medium. This method replicated the target cell
density of the previous methods, while depositing cells inside the scaffold manually.

3.1.2 Viability assessment and cell number.
Scaffold sections produced for viability testing and seeding efficiency analysis were placed in 1000
μl of full growth medium supplemented with 100 μl of alamarBlue (BioRad; Hercules, CA, USA). The
samples were incubated for 4 hours at 37 C with intermittent shaking. After incubation, 200 μl of the
solution from each sample was placed into separate wells of a 96 well plate. Viable cells reduce resazurin,
the active ingredient in alamarBlue, to resorfin which is highly fluorescent. This reaction was quantified
with the hybrid microplate reader BioTek Synergy H1 (BioTek; Winooski, VT, USA). The cell number
was obtained with a standard curve calculated using known concentration suspensions of cells from 25,000
– 275,000 cells in increments of 25,000.
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Additionally, the spatial organization of viable cells was determined via a live/dead viability assay
kit (BioVision, Waltham, MA, USA), which marks live and dead cells based on membrane integrity and
esterase activity. Ethidium homodimer-1, enters cells with a compromised plasma membrane to bind DNA
and emit a red fluorescence. Living cells are identified by Calcein AM, a fluorogenic dye that can permeate
through the cell membrane to be converted to a green fluorescence after interaction with intracellular
esterase. The middle section of 4 bioreactor-mediated perfusion-seeded scaffolds where harvested and
incubated in a 1000:1:2 mixture of PBS, ethidium homodimer-1, Calcein AM for 15 minutes. ETVG
circular cross-sections sections were cut into 3 sub-sections and grid-imaged from the luminal surface on a
Nikon C2 confocal microscope system in z stacks of eight to twelve 16 μm slices. Images where stitched
together using a 3D image stitcher plugin available through FIJI image manipulation software145.

3.1.3 Immunohistochemical assessment.
Scaffold sub-sections produced for spatial distribution analysis with haematoxylin and eosin stain
(H&E) were fixed in 10% neutral buffered formalin overnight. Sections were stained en bloc with H&E
and embedded in OCT Compound (Electron Microscopy Sciences; Hatfield, PA, USA) to cut 8 μm-thick
cross-sections. Stained cross sections were imaged with an Eclipse LV100D microscope (Nikon
Instruments; Melville, NY, USA)
Additional spatial distribution analysis was conducted by staining cell nuclei with DAPI. Scaffold
sub-sections were harvested from the bioreactor and briefly rinsed in PBS before fixation in ice cold
methanol for 5 minutes. Similar to the H&E samples, sections were stained en bloc before embedding in
OCT medium and cutting. After fixation, scaffolds were rinsed in three 5-minute PBS baths. Membrane
permeabilization was achieved by submersion in room temperature 0.1% Triton solution for 15 minutes.
This was followed by another set of three PBS rinses and incubation with 300 nM DAPI solution for 5
minutes. Sections where imaged at 10x on the confocal microscope.
Raw H&E images were converted to binary with ImageJ software137. Binary images were postprocessed to remove artifacts not relevant to analysis. Total cell load was determined by the total area of
47

cells present (i.e. area of black pixels in the image). Circumferential cell coverage was calculated by
measuring the length of the perimeter covered by cells and dividing by the total luminal perimeter of the
scaffold. Average cell-layer thickness was determined by dividing the total cell load by the length of the
perimeter covered by cells.

3.1.4 Scanning electron microscopy (SEM) assessment.
Scaffold sections produced for surface coverage analysis were cut along the top most edge and
placed in 10% neutral buffered formalin solution overnight. Sections were then rinsed 3x in PBS before
dehydration in a series of graded ethanol (ETOH) washes from 50% to 100%. Chemical drying was
achieved with graded washes of ETOH and hexamethyldisilane (HMDS) (MilliporeSigma; Burlington,
MA, USA), followed by submersion in HMDS until fully evaporated.
After dehydration was completed, samples were mounted for imaging with the luminal side of the
scaffold facing up and the circumferential direction corresponding to the horizontal direction of the sample.
Samples were handled such that the middle section represents the bottom most section of the scaffold during
seeding. Samples were gold sputter coated (Cressington 108, Ted Pella; Redding, CA, USA) and imaged
with scanning electron microscopy (Phenom ProX Desktop SEM, NanoScience Instruments; Pheonix, AZ,
USA) operated at 15kV. Imaging was conducted at 300x in a 3x3 grid across the full surface of the scaffold
section to best approximate total surface coverage.
Raw SEM images were converted to binary with the ImageJ plugin DiameterJ Segment 137. Of the
multiple binary images created from each raw SEM image, the one that was the most accurate in
determining where cells were located (i.e. the black spaces in the image covered wherever cells were present
in the original) was chosen for further evaluation. Another ImageJ function, Analyze Particles, was then
employed for the quantification of percent area coverage. Binarized images were checked to determine the
general accuracy of the segmentation method before reporting. Accuracy was determined by randomly
selecting 5 images from each seeding method and comparing results with cell coverage determined by
manual segmentation.
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3.1.5 Statistics.
For all the analysis, three to four samples were used (n = 3+1). Values were reported as the average
of all the samples, and the error was reported as either the standard deviation or 95% confidence interval
(CI) in cases where the standard deviation was larger than the mean. The effect of seeding method and
scaffold section within the seeding method on cell viability, surface coverage, and cell layer thickness were
assessed with a standard ANOVA, and multiple pair-wise comparisons were carried out using the TukeyHSD method. Differences were considered significant if p ≤ 0.05.

3.2 Results
3.2.1 Viability assessment and cell number.
The seeding method had a significant effect on the number of viable cells present per section on
electrospun PCL tubular scaffolds (p=0.005). The average number of viable cells present per sample by
method is 282,598 ± 53,957 cells, 237,220 ± 43,243 cells, and 163,929± 110,537 cells for BMP seeding,
SIC seeding, and drip seeding, respectively. While these averages are not significantly different, the number
of viable cells by section showed that perfusion-driven seeding results in significantly more cells by section,
56,519± 15,463 cells, than drip seeding, 42,182± 29,725 cells (p=0.04). The average number of viable cells
by section of SIC seeding, 47,444± 15,437 cells, was not significantly different than BMP seeding or drip
seeding and the level of variability in longitudinal cell distribution between samples was high.
Perfusion-driven seeding also resulted in the most consistent pattern of cell distribution of the three
methods. While section 1 consistently resulted in lower numbers of viable cells than sections 2-5, sections
2-5 were indistinguishable (with p > 0.95, Fig 18 A). SIC seeding also showed no significant difference
between sections and when averaged showed a normal distribution pattern with higher concentration of
cells in section 3, the middle of the scaffold (Fig 18 B). The standard deviation between SIC samples was
larger than in BMP seeded samples, showing that while there is no observable significant difference
between averages, the results were not as consistent. Drip seeded scaffolds did have a distinct pattern of
cell distribution identifiable in all samples analyzed (Fig 18 C). Drip seeding did not achieve uniformity
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across the entire length of the scaffolds, most cells were found at either end of the scaffolds, sections 1 and
5, with very few to be found in the middle section. Sections 1 and 5 were found to be significantly different
from sections 2, 3 and 4 (p=0.01, 0.0009, 0.009 and p=0.03, 0.0003, 0.003 respectively, the latter set not
included in Fig 18 C).

Figure 18. AlamarBlue viability assay results. Section average viable cell numbers for (A) perfusion
bioreactor seeding, (B) static counterpart seeding, and (C) drip seeding. (n = 4; mean with 95% confidence
intervals.)
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The live dead cell imaging of bioreactor mediated perfusion seeded scaffolds revealed a thick,
confluent layer of living cells covering approximately two thirds of the scaffold luminal surface (Fig 19).
The 4 other scaffolds evaluated this way also follow this pattern. Non-viable cells can be found amongst
the live cells, but they are mostly concentrated near the edges where the scaffolds sub-sections were cut,
and along major defects in the scaffold structure. The third section of the scaffold that does not contain a
confluent layer of cells shows small live cell clumps interspersed throughout the area.

Figure 19. Spatial live/dead cell imaging. The middle section of a perfusion seeded scaffold is represented
in 3rds.The left most portion is the top right edge of the scaffold, the middle portion is the bottom of the
scaffold, and the right most portion is the top left side of the scaffold. Each section length was approximately
5mm, and its circumference was 6.28mm.
In summary, BMP seeding resulted in the most viable cells with the most consistent distribution
across the samples. SIC seeding resulted in a comparable number of cells but with a more inconsistent
distribution, and drip seeding resulted in the least number of cells but a high degree of consistency in
distribution pattern that featured most of the cells focalized at either end, and middle sections remaining
bare.
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3.2.2 Immunohistochemical spatial distribution analysis.
BMP seeding resulted in the most consistent cell coverage across the five sections in terms of cell
presence around the circumference, though cell-layer thickness varied spatially (Fig 20). Both the SIC and
drip seeded samples resulted in cells restricted to a few smaller locations, with inconsistent coverage
between sections, and variable thickness of cell layers within each section, often settling in clumps and
large regions remaining bare. Drip seeding in particular resulted in multiple sections entirely without cells,
usually sections 2-4. Due to such, quantitative analysis was conducted on the BMP and SIC seeded scaffolds
only. Perfusion-driven seeding consistently showed cells dispersed across about 60% of the scaffold area,
with the highest concentration being located along the bottom edge of the scaffold. BMP seeding also
resulted in sporadic cell patches occasionally adhered to the top edge of the scaffold, something rarely seen
in SIC or drip seeding methods.

Figure 20. H&E cross-sections. Representative haematoxylin and eosin (H&E) stained cross sections of
each seeding method 24 hrs after seeding in longitudinal order.
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DAPI stained cross sections show a similar distribution of cells when compared to H&E stained
sections, with emphasis on individual nuclei (Fig 21). This confirms that the cell layer deposited by
bioreactor-mediated perfusion-seeding is indeed composed by cells with DAPI stainable nuclei and
typically one layer thick covering > 60% of the luminal surface. DAPI results obtained with both static
methods corroborate H&E histology showing inconsistency in the cell layer thickness and circumferential
distribution between sections.

Figure 21. DAPI cross-sections. DAPI stained nuclei of cells in cross sections of each seeding method 24
hrs after seeding in longitudinal order.
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Quantitative analysis of histology sections largely agrees with viability results. BMP seeding
resulted in a significantly higher total cell load being deposited to the scaffold lumen than SIC seeding
(p=0.007, Fig 22 A and 22 C). The variability of total cell load and average cell-layer thickness between
sections in the SIC seeded samples corroborates with variations observed in the cell viability analysis (Fig
22 B). Though there was no significant difference in the average cell layer thickness between the two
methods (27.8 vs 29.1 μm), the standard deviation was observed to be larger for individual sections in the
SIC method. The proportion (or percentage) of circumferential coverage between BMP seeding and SIC
seeding was significantly different (p<0.0001), on average achieving 62.8± 20.7 % and 23.6± 15.2 %
respectively.

Figure 22. Quantitative assessment of uniformity. Quantitative analysis of H&E images for bioreactor
mediated perfusion and static injection counterpart seeding methods preformed with rVSMCs onto
electrospun PCL scaffolds. Uniformity judged in terms of total cell load, average cell layer thickness, and
% circumferential coverage per section. (n = 20, n=15; mean ± standard deviation).
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In summary, BMP seeding achieves significantly more cell load and percent circumferential
coverage than static methods while also maintaining a consistent cell layer thickness and distribution
between all five sections.

3.2.3 SEM surface coverage analysis.

Figure 23. Interpretation of SEM images. (A) Representative SEM images of luminal surface of seeded
electrospun PCL scaffolds for each seeding method, (B) Sample images representing quantitative analysis
of luminal surface coverage per method. (C) Zoomed in view of perfusion seeded scaffold.
Analysis of the topography of scaffold sections agrees with viability and histology results. BMP
seeding showed consistent coverage across the full scaffold surface (Fig 23 A) Additionally, perfusion55

driven seeding resulted in individual cells spaced apart from each other while both static methods led to
clumps of cell aggregates from which individual cells could not be identified in the SEM images (Fig 23
B). Cells tend to concentrate along the bottom of the scaffold (middle column of the SEM 3x3 sample
views) in the SIC method, and drip seeded scaffolds showed large concentrations of cells at the ends while
typically achieving fuller surface coverage in these sections. BMP seeded cells did not appear to be
damaged from the perfusion treatment, the morphology of the individual cells qualitatively showed
evidence of adherence to the scaffold surface (Fig 23 C).

Figure 24. Quantitative analysis of surface coverage. Color map of surface coverage and section averages
respectively for (A,B) perfusion bioreactor seeding, (C,D) static counterpart seeding, and (E,F) drip seeding
(n = 36; mean with 95% confidence intervals).
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Quantitative analysis shows that BMP seeding resulted in significantly higher surface coverage
across the scaffold surface, 72.7± 21.7%, when compared to static methods, which averaged 37.4± 25.8%
and 37.7± 24.7% (p<0.0001, Fig 24 A vs. 24 C and 24 E respectively). BMP seeded sections did reveal a
gradient of increasing surface coverage from sections 1 to 5, i.e. upstream to downstream. Sections 1 and 2
on average achieved significantly less surface coverage than section 5 (p=0.002 and p=0.004 respectively,
Fig 9B). Though more inconsistent than previous results suggest, the average surface coverage of sections
1 and 2 are 64.6± 26.32% and 65.8± 24.5% respectively, which is still higher than the approximately 37%
surface coverage achieved by either static method per section on average. The percent area coverage in SIC
and drip seeded scaffolds were variable between sample sections. The distribution pattern for SIC scaffolds
tends to be along the bottom edge of the scaffold with patches of high cell density, while drip seeded
scaffolds tended to have more surface coverage at either end. Both static methods show a high level of
intra-sample variability in cell distribution, either along the length or the circumference of the scaffolds.
(Fig 24 B, D, F) Analysis of accuracy showed that manual segmentation vs. automatic segmentation did
not deviate more than 2% in the 15 random SEM images analyzed.

3.2.4 Combined results.
Establishing correlations between the data reveals that BMP seeding resulted in the most consistent
seeding pattern across all five sections (grouped in blue in Fig 25). When comparing the number of viable
cells to percent surface coverage, perfusion-driven seeded scaffolds outperformed static methods in both
aspects, achieving comparable viable cell load with higher cell coverage (> 60% vs. < 50% of either static
method, Fig 25). Comparing the number of viable cells obtained from the alamarBlue viability assay to the
total cell load determined by histology resulted in a linear correlation (Fig 25). Correlation of histology
determined cell load or SEM-determined surface coverage vs. cell-layer thickness demonstrated again the
improved performance and consistency achieved with perfusion-driven seeding method compared to static
methods (Fig 25).
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Figure 25. Scatter plots of combined data. The top left graph compares the average number of viable cells
present on each scaffold section to the surface coverage determined with SEM analysis. The top right graph
compares the number of viable cells and the cell load area as determined by H&E analysis. The bottom left
graph compares the average cell layer thickness to SEM surface coverage and the bottom right graph
compares cell layer thickness to cell load. Bioreactor mediated perfusion data is highlighted in blue..

3.3 Discussion
Automatic seeding within bioreactors has the benefit of limiting the manual handling of scaffolds,
which in turn limits possible contamination scenarios. Due to this major benefit, it has been investigated
repeatedly since its initial development in 1990 by Wildevuur and coworkers146. Originally, this method
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was developed as a quick way to seed vascular grafts during the operating procedure at the patient’s bedside.
In one exploratory study by Noishiki et al., an 8 cm section of vasculature was finely minced and suspended
in 20 ml of physiological saline solution. The resulting suspension was pushed transmurally through the
lumen of a highly porous fabric scaffold via repeated pressurized injection147. After implantation in a canine
model, it was reported that the grafts experienced increased thrombus formation; however, localization of
cell types to their natural physiological locations was also observed and after 14 days the grafts were
reported to be fully endothelialized. This result was initially promising, but the study failed to address the
rapid transanastomotic endothelial outgrowth observed in animals, and the requirement of a sacrificial
vessel fragment for the seeding does not reduce patient risk associated with multiple surgeries.
Since then, several groups have developed and employed other perfusion-based methods to create
small diameter ETVGs. Feijen and co-workers have cannulated porous tubular polytrimethylene carbonate
scaffolds with 3mm inner diameter in custom-made glass flow chambers and injected 20 ml of SMC cell
suspension through their lumen76,148. The cell suspension was injected with two syringes, one positioned at
either end of the scaffold. Scaffolds were manually rotated every 30-60 min during the first 2.5 hours after
seeding to promote homogeneous cell adhesion, and cultured with either static or dynamic flow conditions
up to 14 days. Cell presence after 7 days was observed transmurally throughout the bulk of the scaffold.
However, a full analysis along the scaffold length or circumference was not demonstrated, so more detailed
spatial distributions of cell seeding could not be determined. Furthermore, rotating after injection when
dealing with thick, porous scaffolds, is counter intuitive, as a dense pore network may impede cell migration
due to gravity. This is supported by the study observation that thicker scaffolds took a longer time to seed,
suggesting the structure impeded cell movement within the scaffold thickness. If in fact the study achieved
a homogenous circumferential distribution, it would be interesting to see if a similar result could be
achieved without the rotation period.
Vorp and colleagues have developed and refined methods for seeding of vascular grafts that
combine double injection filtration perfusion, vacuum perfusion and a rotational element concurrently103,105.
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Studies were conducted to examined the effectiveness of the seeding method on two distinct scaffold types
149

. One had small pore sizes and infiltration into the scaffold thickness was limited, while the other

contained larger pores and allowed cellular infiltration. Cell distribution across the full length of the scaffold
was investigated and found to be homogenous and viable in both cases. Furthermore in 2020, Cunnane et
al. revised the system to accommodate grafts with lengths comparable to those used for human arterial
replacement106. Instead of two syringes seeding the graft at both ends, a diffuser was inserted into the
scaffold lumen. Over the course of the seeding period, the diffuser would translate across the graft length
while dispensing cell suspension from the distal end. Results indicated that this method also achieved a
uniform distribution both longitudinally and circumferentially with a scaffold six times the length of those
in the previous study (12 cm vs 2 cm). While the results are overwhelmingly positive, the complexity of
the seeding systems and experimental protocol limits further manipulation of the scaffold environment after
seeding as well as limiting similar application to systems that attempt to culture more than one graft at a
time.
Seeded scaffolds were evaluated longitudinally and circumferentially in terms of cell load,
viability, cell layer thickness, and surface coverage distribution. BMP seeding resulted in comparable
numbers of viable cells as static drip seeding and the SIC methods. However, the distribution of the cells
present varied greatly between methods. Drip seeding onto the luminal surface resulted in high
concentrations of cells at either end of the scaffold and very few in the middle, as expected. The SIC and
BMP seeding had similar longitudinal cell distributions, but static injection resulted in 35% less
circumferential coverage on average. Interestingly, our histology analysis revealed a more significant
difference between BMP and static seeding methods in terms of cell load than suggested by the results
obtained in our alamarBlue viability assay. We surmise that the histology washes may have washed away
some of the cells present after static seeding. BMP seeding was seemingly unaffected by this possible
phenomenon, leading us to believe that perfusion not only leads to better cellular coverage but also enhances
cell attachment to our scaffolds.
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Differences in apparent SMC morphology perceived from close inspection of the SEM images
could be related with the phenotypic modulation of SMCs, which could change from synthetic to contractile
if part of a large aggregate as seen in the denser regions of drip seeded and statically infused scaffolds.
Contractile SMCs are elongated, spindle-shaped cells, whereas synthetic/proliferative SMCs are less
elongated and have a cobblestone morphology31. However, SEM imaging is purely topographical and the
boundary between cells can be difficult to define if cells form aggregates with multiple layers and have
deposited ECM into the interstitial space between cells. In the bioreactor mediated perfusion seeding
method, cells are distributed more homogenously and typically in a monolayer, with different degrees of
sparsity, so it is easier to distinguish individual cells from one another. In the other static methods, cells
would typically aggregate in a small region of the scaffold area which presents itself as a smooth surface
with individual cells difficult to identify.
There are many limitations associated with the work presented here as there often are with ETVGrelated experiments. To determine feasibility in the clinical setting, the system would need to be scaled up
to the appropriate size. Vascular grafts for human CABG are typically 5 mm in diameter and 18 cm long
resulting in an aspect ratio of 45, compared to the aspect ratio employed here, which is about 20 150,151.
Additional determinations of cell morphology, such as staining with vascular SMC contractile markers like
alpha smooth muscle actin (α-SMA), smoothelin, or smooth muscle myosin heavy chain (SM-MHC) would
provide more information towards determining how the seeding process may affect SMC phenotype and
behavior relevant for the subsequent steps of in vitro culture. Furthermore, we have looked into additive
agents that are used to prevent cell sedimentation in syringes and tubing, but none were used in this study,
which may be considered an oversite when determining the effectiveness of our method. Additive agents
in 3D culture media can be expensive, and there are a great number to choose from. We believe that the
positive results obtained in this study are encouraging and promote the possibility of future studies to tailor
those aspects to address a variety of problems.
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4 Chapter 4

Development of dynamic culture capabilities and analysis methods.

Though the correlation between biophysical stimulation and increased ECM synthesis can readily
be observed, the mechanism behind the interaction remains undefined. The response is undoubtably
multichannel, a highly integrative collection of cellular pathways responding and influencing cell behavior
at the microscopic scale. Studying the response of individual cells to the addition of molecules or
mechanical strain to a system can reveal highly significant information, however, cellular behavior varies
drastically between 2-D and 3-D constructs in vitro152. Progress in the field demands a highly controllable
and consistent microenvironment to study how the effect of physiologically relevant mechanical stimulation
translates to 3D ECM development and organization.
Huang, Niklason and coworkers investigated biaxial mechanical strain as previously mentioned 114.
In the bioreactor system, 3 ETVGs sheathing silicone tubing were seeded with bovine SMCs and cultured
in parallel. One scaffold was used as a static control, experiencing no form of stimulation. The second was
connected to a flow circuit that cyclically pumped PBS through the silicone tube in the ETVG lumen,
facilitating the application of circumferential stretch. The third and final scaffold was also subjugated to
circumferential stretch, but experienced additional application of axial stretch from an axially movable
connector controlled by a linear motor. Prior to the application of stretch, all three scaffolds were cultured
under static conditions for 1 week, then dynamic conditions were applied to the designated scaffold for a
period up to 12 weeks. The axial strain applied to the biaxially developed ETVG was 8% and was
maintained at a rate of 0.033 Hz for the duration of the culture period. Circumferential stretch application
was added a week after axial. Both the uniaxial and biaxial ETVGs experienced a simulated pulse rate of
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245 bpm and achieved circumferential strains up to 2% facilitated by the silicone tubing. After a period of
13 weeks, there was an obvious difference between the ETVGs.
Mechanical stretch resulted in thicker, stronger tissues, and the benefit of biaxial over uniaxial
techniques was pronounced, especially when considering the significant increase in elastin content which
contributed to increase compliance153. Further exploration revealed that not only the composition and
mechanical properties were improved, but also the microstructural organization of the tissue. The ECM of
biaxially developed ETVGs was extensive and highly organized, featuring mature elastin fibers. Collagen
fibers experienced an orientation gradient transmurally through the scaffold thickness from circumferential
orientation along the lumen to axial orientation along the adventitia. Collagen fibers also experienced a
higher level of undulation, a feature relevant to native vasculature. When the elastin was removed in the
constructs, the undulation of the collagen fibers decreased and the ETVG stiffened, suggesting that elastin
functionally was also increased when ETVGs are subjected to biaxial stimulation. Mechanical mismatch
between host arteries and ETVGs is thought to cause blood flow disturbances resulting in pathological
tissue response and neointimal hyperplasia at the distal anastomosis. Higher graft compliance has a positive
effect on graft patency, suggesting that grafts developed this way may reduce graft failure in vivo.
In this study, we sought to address the limitations of the first bioreactor design and further progress
the system towards the reliable application of dual axial mechanical strain on mounted tubular constructs.
The final iteration of the main bioreactor chamber was a 3-D printed construct that features 4 separate
troughs for individual scaffold cultivation. Each scaffold is also on its own flow loop, eliminating possible
crosstalk between samples and further limiting possible contamination scenarios. Tubes facilitating the
transfer of cell media from bioreactor chamber to the reservoirs were placed on the secondary fast-moving
pump while tubes feeding the ETVGs from the reservoirs were on the primary slower moving pump. This
feature aided in reliable fluid level management in the bioreactor system, preventing possible overflow into
neighboring troughs as well as reservoir emptying which introduces air into the scaffold lumen. The
orientation of scaffold culture was shifted horizontally, to ease the application of axial stretch to the system.
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Additionally, the process for cell loading was revised extensively (See Chapter 3). The fully defined design
and experimental procedure is outlined in the following sections.

4.1 Bioreactor V2.1

Figure 26. Bioreactor design. (A) The fully assembled bioreactor chamber. Intake and outtake tube holders
are found on each side of the individual ETVG chambers. (B) An electrospun PCL tubular scaffold mounted
with collet chucks in a four-pronged stainless-steel bracket. The 2mm cannulas affixed to either end of the
scaffold form a tight seal with the tightened collet chucks. This connection makes tensile stretch and luminal
pressurization possible while also leaving the lumen of the ETVG in direct contact with media flow. (C)
Flow diagram within the bioreactor chamber. The red arrow shows media traveling from a reservoir to the
ETVG lumen, the green arrow shows media movement out of the ETVG, out of the bioreactor, through the
pinch valve, and back into the bioreactor. The blue arrow represents media being drawn from the bioreactor
chamber to return to the reservoir. (D) Full schematic of bioreactor flow loop and intended features. Color
coded as in panel C.
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The bioreactor chamber (Fig 26A) was 3-D printed (Stratasys F170, Eden Prairie, MN) with a 13%
infill using acrylonitrile butadiene styrene (ABS) with water-soluble QSR support material. The 3-D printed
bioreactor chamber was coated with resin to prevent fluid leakage. The bioreactor was designed to seedand-culture four tubular scaffolds in parallel channels (175 mm x 38 mm x 25 mm). The tubular scaffolds
are fitted onto 2mm outer diameter stainless steel cannulas on each end such that 30mm of the graft length
was available for seeding. Scaffolds were secured to the cannulas with parafilm and mounted into two 4
pronged brackets with collet chucks (Fig 26B). The brackets are fastened at a fixed distance apart keeping
the 20 mm length of the scaffolds straight and unstressed. Once assembled, the mounting bracket was placed
in the bioreactor chamber and the scaffolds connected to their individual flow paths through the cannulas.

4.2 Experimental Procedure
Robust experimental processes are important for systematic study. Here we outline the procedure
for using the seed and culture bioreactor system. The activities are split up into days, however there can be
periods of inactivity between the active days that span more than 24 hours depending on the experimental
protocol and length of culture period. The described procedures can easily accommodate a variety of ETVG
scaffolds and allow for easy manipulation of relevant culture parameters within a controlled environment
to study the effects of mechanical conditioning on ETVG development.

4.2.1 Day 1
4.2.1.1

Bioreactor Sterilization
The bioreactor chamber is scrubbed thoroughly in warm soapy water and special attention

is payed to crevices which like to harbor bacteria. Following a rinse in clean water, the bioreactor chamber
is sterilized via immersion in 70% ethanol and placed in the BSC. The UV function of the BSC is used to
further sterilize the bioreactor interior as it air dries. The bioreactor chamber can be stored in the BSC to
maintain sterility until it is used.
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The ETVG mounting bracket assembly is disassembled, and each piece thoroughly scrubbed with
ultrafine steel wool and soap. Assembly pieces are rinsed once in clean water and once in 70% ethanol
before being left to air dry. Components are packaged by order of assembly in sealable autoclave bags and
subjected to 121 F for 30 minutes. Sterilized components can be stored in their bags indefinitely prior to
use.
Bioreactor tubing remains connected in the culture flow loop following the end of an experiment.
ETVG feeder tubes are connected to bioreactor drainage tubes after removal from the bioreactor chamber.
The system is flushed by filling the culture reservoirs with warm soapy water and the tubes gently massaged
to dislodge possible build up. The system is drained, rinsed with clean water, and drained again before 70%
ethanol is allowed to run through the system uninterrupted for 1 hour. The tubing is then fully disassembled
and allowed to dry. Cell reservoirs and extraneous pieces of tubing are washed separately following the
same procedure but using a syringe to facilitate the rinsing. Flow loop components are packaged by order
of assembly and autoclaved at 121 F for 30 minutes. Sterilized components can be stored in their bags
indefinitely prior to use.
4.2.1.2

Scaffold Preparation
The following method is specific for use with electrospun PCL scaffolds. To reduce the

hydrophobicity of the PCL material, processed scaffolds are submerged in 1M NaOH solution (pH = 12)
for 4 hours. Scaffolds are then rinsed x3 via submersion in 10 ml of DI water and 5 minutes on the shaker.
Following the DI rinses, scaffolds are placed into sterile test tubes and totally submerged in 70% ETOH
over night to sterilize.

66

4.2.2 Day 2
4.2.2.1

Scaffold Mounting
In the biosafety cabinet, the bioreactor box tubing is assembled. This includes the ETVG feeder

tubes, ETVG exit tubes, and bioreactor drainage tubes. The bioreactor drainage tubes are sealed off to
prevent contamination access when not hooked into the full flow loop.

Figure 27. Mounting scaffolds into the bracket assembly. A) Scaffolds are fastened into the bracket
assembly via a collet chuck assembly featuring a base, stainless steel collet, and a taper. B) The scaffolds
are secured to the 2mm stainless steel cannulas, by tightly wrapping with parafilm. C) The collect is then
slide into place on the cannula, with the front face planar to the end of the cannula and fastened into the
base with set screws. The collet is then tightened via the taper screw, holding the scaffold securely in place.
D) This process is repeated on the other side. Due to one end already being secured, the opposite taper
screw needs to be gently slid over the scaffold material before collet placement.
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Sterilized scaffolds are secured between 4 cm long metal cannulas via parafilm wrap (Fig 27 B).
One of the four pronged brackets is secured into a specially designed mounting table, and a collet chuck
base is screwed through each prong. One collet is slid into place, entrance parallel to the end of the cannula
concealed within the scaffold material and parafilm wrap, for each scaffold (Fig 27 C). The collet is slid
into its appropriate base and its position secured with set screws in the base. Then each collet is tightened
by screwing on the taper. For each scaffold, the other taper is slid over the opposite cannula until it sits face
to face with the first taper, then the second collet is slid into place on the opposite end, with its entrance
parallel to the end of the second cannula hidden by the scaffold material. The whole construct is then very
carefully manipulated to coax the remaining cannulas into the bases on the second 4 pronged bracket (Fig
27 D). The cannulas are fixed into the appropriate position via set screws and the collets are tightened by
screwing on the tapers. The two brackets are fastened a fixed distance apart via threaded rods, and tubing
connecters fixed to each cannula end to facilitate insertion into the bioreactor flow circuit. The proximal
entrance of the ETVG is connected to the ETVG feeder tube, and the distal end is connected to the ETVG
exit tube.

Figure 28. Comparison between the static and dynamic bioreactor chamber assemblies. The main difference
between the static and dynamic bioreactor chambers correlates to the bracket assembly. In static culture,
scaffolds are held at a fixed distance apart, so the only bracket attachment required is between the two
brackets themselves (left). The dynamic assembly requires one bracket to be fixed in relation to the
bioreactor wall, while the other can move in relation to the linear actuator positioned outside of the box. To
achieve this affect, 2 linear motion bearings were set into the bioreactor wall to allow the passage of linear
motion shafts (right).
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For static culture, the rods fastening the 4 pronged brackets together are kept and the whole
assembly simply placed into the static bioreactor box (Fig 28). However, scaffolds undergoing dynamic
culture will be culture in the dynamic box. The dynamic box assembly features and additional step securing
the distal 4 pronged bracket to the bioreactor box edge and the proximal 4 pronged bracket to linear shafts
connected outside the bioreactor chamber by a bracket that facilitates connection to a linear actuator. Once
the brackets are secured properly, the original rods connecting the 4 pronged brackets are removed and the
system fit for dynamic culture.
4.2.2.2

Prewetting
A sterile 10 ml syringe is filled with 70% ethanol and connected to the ETVG feeder tube. The

solution is pushed through the scaffold slowly to flush any final possible impurities from the assembly. An
additional syringe filled with sterile PBS is flushed through the scaffold the same way. Following this step,
the ETVG exit tube at the distal end of the bioreactor is clamped shut, and an additional syringe of sterile
PBS flushed through the scaffold at a rate of 20ml an hour with a syringe pump. This step is repeated with
an additional syringe of sterile PBS. Following this rinse, the excess fluid in the bioreactor is aspirated and
a fresh syringe filled with full culture medium is connected to the ETVG feeder tube. The clamp on the
ETVG exit tube is undone and the bioreactor exit tube is fully flushed with medium. Immediately following
this the exit tubes are clamped again and the whole assembly placed into an incubator over night for scaffold
prewetting.

4.2.3 Day 3
4.2.3.1

ETVG Seeding

Day 3 is seeding day. Cell seeding onto the scaffold is fully characterized in CH3 and Publication reference.
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4.2.4 Day 4
4.2.4.1

Static Culture
After the seeding period, the 4 ETVGs within the bioreactor are switched into culture mode each

with their own independent flow loops. For static culture, the switch is relatively simple because the only
requirement is insertion into the bioreactor flow loop. The bioreactor flow loop is primed by connecting the
tube destined for the ETVG feeder connection and the tube destine for bioreactor draining, filling the media
reservoir with full culture medium and using the peristalitic pump to drive flow though the tubes, priming
the system. Clamps are used to seal the feeder tube and the drainage tube prior to their disconnection. Once
disconnected, the tubes are fastened to the appropriate ports on the bioreactor box and the system is ready
for slow flow static culture.
Culture medium is drawn from the media reservoir with a peristaltic pump, and pushed through the
ETVG lumen, and returned to the ETVG chamber. For fluid level balancing in each ETVG system, an
additional flow line draws media from the bioreactor chamber back to the media reservoir. The intake and
outtake tubes are located at opposite ends of the ETVG chamber, facilitating gentle media flow around the
outer surface of the scaffold during culture.
4.2.4.2

Dynamic Culture
For dynamic culture, the bioreactor box with specialized bracket connections is fastened into the

specially design dynamic breadboard featuring a linear actuator (Fig 29 B), 4 pressure sensor connections
(Fig 29 C), and 4 parallel pinch valves (Fig 29 D). The bioreactor chamber is hooked into the flow system
as previously described. The box is placed onto the dynamic breadboard, and the linear shaft connecting
bracket slid into place on the linear actuator shaft and secured with a stainless-steel nut. The base of the
bioreactor chamber is then secured to the dynamic breadboard in each corner by 4 screws. The ETVG exit
tubes are securing into the pinch valve chamber, and pressure sensors plugged into their appropriate ports.
Additionally, a single Texas Instruments data acquisition board controls all the electronic components of
the bioreactor.
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Figure 29. Dynamic culture components. A) The fully assembled dynamic breadboard. Four screws denote
intended bioreactor placement. Demonstrations of connections to the actuator (B), pressure sensors (C),
and pinch valves (D) are also shown.

4.2.5 Day 5
4.2.5.2

Media Switch
Once a week following the start of slow flow static culture, the media will need to be replace in the

bioreactor system. This process is begun by turning the peristatic pump facilitating bioreactor draining of
and allowing the reservoirs to drain nearly completely into the bioreactor chamber. Media is then aspirated
from the bioreactor chamber, and the reservoirs filled with 100 ml of fresh culture medium, warmed to 37
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in the hot water bath. The entire system is returned to the incubator and connected back to the peristatic
pumps to resume normal culture conditions.
4.2.5.3

Dynamic Programming

A custom user interface was developed to control the bioreactor system in LabView (Fig 30). The
user can adjust all inputs to control the pump velocity, axial stretch, max pressure, time to hold pressure,
number of cycles, etc. The fine control over these parameters allows for future experimentation with
different mechanical stimulation procedures on the scaffolds. Base controls of the program included the
ability to remotely turn the pump on at a desired speed. This is useful to prime the bioreactor system with
media prior to culture start and remove bubbles that may interfere with pressure measurements. You also
have the ability to control the pinch valve to open and close remotely and tare the pressure sensors. Initial
actuator position can also be set before starting an experiment. It is important to note that the number
designated to move the bioreactor is in relation to its absolute position, not its current position. The program
facilitates the recording of data to any text file designated by the file path, and the sampling rate can also
be defined.
Experimentally the program allows you to exert influence over the mechanical conditioning regimen
in the follow order. At t = 0, the parameter you dictate is pump velocity, which is the default value the pump
will take if it is turned on. The length of time the pump is held at this speed without the addition of
stimulation can also be dictated. The next phase incorporates graft pressurization with controls over pump
velocity 2, the speed for pressure buildup, and the period of pressurization by closure of the pinch valve.
Pressure can be held for a specified time, which the program facilitates by turning the pump off while
keeping the pinch valve closed. This step is critical for evaluating possible ETVG leakage, signaled by
decreasing pressure during this period. At the end of the specified time the pinch valve is released and flow
allowed to resume. The next phase incorporates axial stretch with dictated strain and hold period. Axial
strain and circumferential pressurization cannot be exerted concurrently by the program unless a significant
is place on the ETVGs through setting of the initial actuator position. The cycle switches back and forth
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between circumferential and axial stimulation, but either phase may be programmed to repeat a set number
of times in their block. Also, a wait period can be established between each action. The bioreactor program
can be run indefinitely in theory, but we suggest that stimulation be applied periodically, over periods of 6
hours or less, in order to reduce stress on electrical components.

Figure 30. Programming dynamic culture. The LabVIEW interface (top) can be used to dictate the period,
magnitude and pattern of circumferential and axial stimulation. Each of the dynamic culture components
(bottom) can also be controlled individually via DAQ board connection.
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4.3 Biaxial Mechanical Tester
Determination of the mechanical properties of cultured ETVGs is an essential part of future studies
evaluating the effect of mechanical strain on tissue development. A custom designed biaxial mechanical
tester was created for this purpose and has been a useful tool for testing the conditioning programming
capabilities of the bioreactor.

4.3.1 Biaxial Mechanical Tester Assembly
The biaxial tester assembly can facilitate mechanical property measurements both in open air and
submerged in liquid through a custom-designed 3D printed mounting stage (Fig 31). When recording
measurements of submerged scaffolds, it is essential that the camera is recording through a window in direct
contact with the medium to prevent possible image distortion. The design features a clear, bottom panel
and lifted stage such that the camera may be mounted to record from the bottom of the assembly.

Figure 31. Biaxial mechanical tester. The center box (1) houses mounted scaffolds. The center box may
be modified to hold the scaffold submerged underwater. The bottom of the box is clear plastic to facilitate
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camera viewing from the bottom. A linear actuator (2) mounted via support brackets provide axial stretch.
The system is composed of a peristaltic pump, load sensor (3), and pressure sensor downstream.
Measurements of circumferential hydrostatic pressure is facilitated by an in-line pressure sensor
located at the distal end of the scaffold in relation to flow. Pressure is applied via the closing of a pinch
valve at the distal end of the pressure sensor. Measurements of tensile force exerted by the actuator at the
proximal bracket are facilitated by a load cell fastened to the distal bracket.

4.3.2 Geometry and Stress Calculations

Figure 32. Geometry monitoring. Scaffolds mounted in the biaxial mechanical tester system are evaluated
by tracking the change in diameter and distance between three markings place on the scaffold surface via
LabVIEW monitoring software (top). The biaxial mechanical tester is a useful to for evaluating possible
dynamic culture conditions. Silicone tubes were mounted in the tester and subjected to conditioning cycles
similar to those programmed by the dynamic bioreactor. Measurements corresponded to the activation of
dynamic components.
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A computer vision program was implemented for tracking the circumferential and axial strain
response of the scaffolds (Fig 32). Grayscale-based edge tracking of the scaffold reports changes in the
diameter. For the axial component, three dots are drawn on the scaffolds and the distances between them
are used to detect stretch on the scaffold. The computer vision measurement system was capable of
recording deformations less than 0.1mm in the scaffolds. Camera measurements are compared to
measurements of tensile force and hydrostatic pressure to determine the stress experienced by the material
and the material stiffness.

4.4 Discussion
Before the success of Huang and coworkers, a bioreactor for the biaxial mechanical stimulation of
vascular constructs was developed by Mironov and colleagues154. The design supported the recording of
diameter and pressure during culture with the incorporation of a camera and pressure transducers and is one
of the earliest documented attempts at applying axial strain to arterial constructs. Zaucha and colleagues
later developed a more sophisticated version featuring a computer-controlled bioreactor and biomechanical
testing system capable of (i) enabling simultaneous and independent control of circumferential pressure and
axial load on TEVs; and (ii) performing biaxial mechanical testing on the same vessel at multiple timepoints in culture. Additionally, a multi-photon microscope was incorporated to facilitate real time imaging
of active ECM synthesis and organization within the bioreactor under a variety of loading conditions 155.
The bioreactor proved to be a thorough tool for the study of ETVG development, however due to the
system’s complexity only one vessel could be cultured and examined at a time. Additionally, the cost
associated with such high-definition monitoring equipment is significant. Commercially made bioreactors
such as the Bose ElectroForce BioDynamic Test Instrument and the Tissue Growth Tech LumeGen
Bioreactor are designed to conduct mechanical testing on vascular constructs have been developed,
however such systems were not developed with ETVG manufacturing in mind and the cost is often
prohibitive.
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To our knowledge, the bioreactor system presented here is the first to be developed that incorporates
semi-automated cell seeding and subsequent culture in a system conducive to the application of biaxial
mechanical stimulation on four small diameter tubular scaffolds simultaneously and independently. To
culture multiple ETVGs in parallel greatly increases experimental through put, facilitating rapid progress
in the field. The variety of conditioning regimens that can be facilitated by the system combined with its
ability to adapt to scaffolds of different lengths, diameters, and structures make it a versatile and costeffective tool for the rapid study of ETVG development under the influence of mechanical forces. The plug
and play nature of the bioreactor chamber simplifies the design and reduces cost. The ability to conduct
tissue engineering experiments in a cost- and resource-effective experimental program is crucial to refine
methods and obtain reproducible and statistically reliable data to provide a better mechanistic understanding
of engineered tissue growth and remodeling during its in vitro incubation stage.

Figure 33. Initial results of in vitro culture using the bioreactor system. Scaffolds were seeded as previously
described and allowed to rest for two days before hooked into the culture flow loop. ETVGs pictured
experienced 3 days of slow flow through the lumen. Circumferential distribution of cells was improved
over the 24 hr time points previously evaluated.
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Electrospun PCL scaffolds seeded with rat vascular smooth muscle cells have been successfully
cultured in the bioreactor for a period of 5 days without becoming contaminated (Fig 33). On the second
day, the system was exposed to slow flow of approximately 2 ml/min. Initial histology revealed ETVGs
developed improved surface coverage when compared to samples 24 hours after seeding, as described in
Chapter 3. This suggests that cell adhesion to the scaffold is strong enough to with stand mild shear stress
exposure, which is a promising initial result. The protocol needs to be optimized in terms of how long tissue
is allowed to develop before external forces are applied. Starting dynamic conditioning too early can result
in scaffold leaking due to insufficient tissue development and dislodging of developing tissue from the
scaffold. Following continued experiments characterizing the basic effects of mechanical stimulation on
ETVG development, running experiments with different scaffold types to see if experimental application
and results are conserved would strengthen the study considerably. One area of concern is pump placement
in relation to the bioreactor. Tubes linking the bioreactor chamber to the reservoirs run out of the incubator
and through a peristatic pump before returning. Cooling of media due to this exposure has resulted in
increased condensation on the lid of the bioreactor box, which eventually redistributes the fluid between
ETVG flow loops. During periods of extended ETVG culture, this is combated by insulating the tubes
outside of the incubator. Moving the pumps into the incubator would eliminate this effect, but the size of
the pumps in relation to the incubator limit the feasibility of this option. Possible solutions include buying
a different pump or a larger incubator.
The biaxial tester uses methods similar to other biaxial mechanical testing systems to determine
axial and circumferential strain, further validating our adoption of the method129,155. Ultimately, combining
the two systems would allow for real time monitoring of mechanical properties providing valuable insight
into the stages of ETVG development. Until then, the current tester needs to be modified to accommodate
specimens of native vasculature. Physiological specimens can be notoriously difficult to hold for
mechanical testing applications, often requiring some sort of suture or treatment that hardens a section of
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tissue, making it easier to grip. Testing the mechanical properties of native vessels provides target values
for ETVG development.
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5 Chapter 5

Conclusion and Future Work

Overall, there is a trend in the field of tissue engineering to bridge the past 50 years of empiricallybased trial-and error experimentation towards a rational approach based on engineering principles and
critical reasoning90. Developing a thorough understanding of the underlying structural and mechanical
factors responsible for the formation and maturation of functional ECM structures remains elusive, but
significant progress is being made in characterizing the macroscopic effects of multiaxial mechanical
loading in 3D tissue development.
The methods outline in each chapter of this dissertation describe a pipeline for the evaluation of the
effects of mechanical conditioning on ETVG microstructure, stiffness, mechanical properties and patency.
Bioreactors are a premier tool for studying the effects of environmental stimuli on ECM remodeling and
ETVG development. The concurrent development of 4 ETVGs under identical conditions is a novel concept
which will facilitate a quicker rate of discovery in the field. Additionally, carefully developed user
interfaces mediate the easy programming of mechanical conditioning regimens with a high degree of
specificity. Finally, due to the design simplicity and the primary use of generic parts, the described
bioreactor can be modified to accommodate grafts of different sizes and structures relatively hassle free.
The development of this vital tool not only marks the transition of vascular tissue engineering from a field
of empirical discovery to one of systematic characterization but contributes significantly towards progress
in the field.
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5.1 Dynamic Conditioning Characterization
While studies similar to ours have revealed the paramount importance of vascular
mechanotransduction, they do not achieve actual quantification due to the fact that they focus on single
level conditions – i.e., no stretch vs. a single level of stretch. With the bioreactor we can begin to evaluate
the extent mechanical stimulation can be utilized to affect ETVG properties. Our hypothesis is that different
levels of strain magnitude and frequency will result in ETVGs of varying microstructural and mechanical
properties. By fine tuning the relevant range of mechanical stimulation for ETVGs we can save time and
resources in future experiments.
The bioreactor will also be modified to conduct hands free, non-destructive testing of mechanical
properties during culture so we can measure the response to mechanical conditioning in real time.
Intermittent biomechanical testing in combination with detailed structural analysis will allow us to gain
further insights into both microstructure influence on tissue level biomechanics as well as constituent
production, removal and reorganization in response to mechanical stimuli.

5.2 Characterization of Foreign Body Response in vivo
The ultimate goal is to be able to predict the in vivo response to ETVGs with different properties.
The implantation of a biomaterial into the body initiates a foreign body reaction. This begins with protein
absorption and acute inflammation, then typically chronic inflammation, and in some cases leads to
granulation tissue formation156,157. Several different factors including extent of the injury created with the
implantation, biomaterial chemical composition, surface free energy, surface charge, porosity, roughness,
and implant size and shape have been indicated to have a role in the duration and extent of each step and
still a lot of research is being performed to better understand this response158.
The duality between fully functional tissue regeneration vs. pathobiological fibrotic repair is
dependent on a multi-phased cascade involving the cause-effect interplay between implant properties, host
reactions, and their modulation with controllable parameters158,159. ETVGs should be designed not to
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diminish host responses, but instead, to trigger desired immunological responses and therefore enable their
integration and subsequent growth and remodeling. Using the body’s own mechanisms to continue ETVG
development in vivo lessens the need for outside involvement such as immunosuppressant drugs and
additional surgeries160. Developing a detailed understanding of this response through systematic
experiments will provide guidelines to achieve cell and tissue homeostasis quickly, while preventing
maladaptive tissue formation.

5.3 Simulating culture environments for improved outcomes
This experimental device promises to provide new insights towards mechanically induced growth and
remodeling of TEBVs. Using experimental results, theoretical models can be developed to mathematically
describe these complex processes. Studies with validated mathematical models have the advantage over
experimental research in that individual parameters can be altered to understand how these individual
components affect the overall function. In addition, the time and cost savings using mathematical models
makes them significantly more valuable.
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Appendix
Developed Protocols
2mm Scaffold Electrospinning
1) First, wrap the 2mm mandrel in aluminum foil.
a. Cut a 1cm thick strip of foil by following the edge of a straight ruler with a razor blade. Cut to the
appropriate length (~ 13 cm) and proceed to wrap carefully around the mandrel. Tighten by rolling
a second time with a piece of paper.

2) Insert the wrapped mandrel in a chuck. With one hand, hold the mandrel in the center of the chuck and with the
other rotate the base to tighten the chuck. Repeat with the top mandrel. Make sure that the mandrel does not lean
in any one direction. If it does, adjust it until it is as straight as possible. Make sure there is 12 cm of mandrel
between chucks.

3)

Insert mounted mandrel into the stage. Slide the golden end into the rotational motor, then fix the opposite side
with the jointed mechanism. Tighten and fix with an Allen wrench.

4) Once the mandrel is mounted test the rotation by flicking the switch of the rotational transformer. If it wobbles
then you need to reposition the mandrel, it was probably not straight. If the mandrel does not wobble too much
then you can proceed. Gently cleanse the aluminum surface with a kimwipe and some acetone.
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5) Turn on the small power supply next to the computer and boot up the computer. Open the IMC for CM/SCX.
Make sure that the window that comes on reads COM3 and 9600. Go to program editor, sequence directory, and
run the Scratch program. This starts your translational motion.

*always stop the motion at the point which it is closest to the edge of the bench. If you do not, when you
restart the motion it will view wherever you stopped as the new starting point. The translational motion can
only go so far and if you start too far down you will hurt the mechanism. To reset go to the first window,
change the distance to -0.5 and press start motion until it is back at the correct starting point.
6) Take a 1ml syringe out of its packaging and collect 1.2 ml of the polymer solution with it. Attach a 27-gauge
needle to the syringe and fill the needle with solution until a small amount comes out of the end.
Insert into the syringe pump and secure with the holder. Move plate until it is touching the end of the plunger.
Check that the infusion rate is set at your desired level.
1.2 ml/hr
7) Attach the gator clip hooked to the main power generator on the
far side of the enclosure to the needle. Slide a small washer over
needle tip to help direct the flow.
8) Ensure that tip of needle is desired distance away from mandrel,
18 cm. Make sure both sides are parallel to the needle by
measuring the distance of the stage from the wall and the far and
near ends. Make sure that the needle is aimed initially at 5cm
from the motor.
9) Set a timer to 40 minutes. Take note of the temperature and humidity in the enclosure and what time you are
beginning your spin.
10) Start the process in this order: Lamp in the enclosure, rotational motor, translational program, infusion, then start
the power and timer at the same time.
The lamp allows you to see the fibers more clearly as you are spinning. Keep an eye on the set up for the
duration of the spin to make sure nothing goes wrong and you are there when the timer ends.
11) When time is up, stop the current. Then stop the syringe pump, rotational motor and translational motor. Take
note of the amount of solution deposited and any general observations you can make on the quality of the scaffold
based on visual inspection.
Turn off the power first when the timer goes off. Do not touch the cord or needle while the power is on or
you will get shocked and it will hurt. Record your spin in the Production Log under scaffold files in the
research folder. See 2mm Scaffold Processing for further instruction.
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2mm Scaffold Processing
1) Label the scaffold on the motor side with its spin number, then remove the foil + scaffold from the mandrel.

2)
Starting on the user end, cut away 1 cm of material
starting at the inner end of the coffee filter section. Then cut another 1 cm section and store in a test tube
with the spin number and date labeled on it. Next cut a 4cm section from the same end of the scaffold. This
is your usable scaffold for experiments. Finally cut one more 1cm section. Put all sections in the test tube.
These sections will be labeled 10, Graft Scaffold, and 5 respectively.
3) Remove the foil from the 10 and 5 pieces with tweezers. These will be used to test the thickness and SEM
of the scaffold.
4) Remove foil from the Graft Scaffold by gently using tweezers. Use the tweezers to reduce the
circumference of the foil within the scaffold by grabbing the inner lip and rolling on both sides, then gently
pull on the aluminum sleeve so it slides out of the scaffold.
5) Measure the mass (mg) and length(mm) of the graft scaffold as well as the thickness (µm) of piece 5 and
record it in the 2mm Scaffold Data Log along with any interesting notes (i.e. Delamination, beading,
interuptions in the spin process, ect.)

Quality Control
*Every 10th scaffold is used for quality control purposes.
1) For these scaffolds, you take the total length of the scaffold (12 cm) and cut off the last 1 cm of both sides.
KEEP TRACK OF WHICH SIDE WAS WHICH.
2) The remaining 10 cm shall be cut into 10 1cm long pieces labeled 1 through 10. Piece 1 corresponds to the
side closest to the motor end and piece 10 corresponds to the operator side.
3)

Each piece will have its mass and length measured as well as thickness. This will be recorded in the
Quality Control Sheet of the 2mm Scaffold Data Log.

4) Add this data to the graphs on the sheet to determine if you are within the acceptable range of
measurements and your scaffolds are usable for experiments.
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Scaffold Mounting
Supplies:
4 scaffolds
8 3.5cm cannulas
8 collet chuck sets ->
2 Brackets
2 mounting rods
4 sets of nuts and washers
Needle nose tweezers
Wrench

Taper

Collet

Inner Sleeve

This protocol takes place in
the cell culture hood to maintain sterility before seeding. Autoclave/sterilize everything before entering the
hood. Inside the hood have a small container of 70% ethanol to keep parts in as you assemble the
bioreactor, rinse interior of bioreactor box with 70% ethanol and allow to dry before setting scaffold
assembly inside.
1) Secure one bracket in the far end of the mounting table frame, set the two support tables next to it.
2) Take one of your scaffolds and confirm that it is 4 cm long. Stretch .5 cm of the ends such that they will fit
over the cannulas.
3) Once the scaffold is .5cm over the cannula, take a small piece of parafilm and use it to secure the scaffold
to the cannula with a leak proof seal. Repeat for the first side of all 4 scaffolds.

4) Carefully repeat the process with the other side of all four scaffolds, being careful to not twist the scaffolds
while doing so.
5) One at a time, slip a collet over the cannula/scaffold connection with the end of the cannula flush with the
face of the collet. Set aside.
6) Fasten each of the 8 inner sleeves into the brackets, as far as they will go. Afterwards, set one of the
brackets into the first slot of the mounting table and position the support tables next to it, as pictured.

7) Carefully slip each collet

from your scaffold/cannulas/collet

assembly into the inner
sleeves of the first bracket. Secure
the cannula in place with the stainless steel setscrews on the base of the inner sleeve. Secure the scaffold
collet with the tapers.

105

8) For the next side, slide the remaining tapers over the partially
mounted scaffolds. (the narrow ends of the tapers should be facing
eachother). Then slide the remaining collets into their correct
position on the remaining cannulas.
9) Carefully remove support table A and slide the second bracket into
its slot on the mounting table. Slide the cannula/collet connections
into the inner sleeves. Before securing with setscrews, confirm that
the exposed section of scaffold is as close to 3 cm long as possible.
Secure set crews and tighten the taper.
10) Carefully slide support Table B out from between the brackets.
Secure the two brackets together with stainless steel rods, wasters
and nuts. Preserve the set space of 3cm between scaffold ends, with
slight tension.
11) Set the assembly into the main bioreactor box, attach designated
polypropylene tubes to their cannulas, and if necessary secure brackets to the bioreactor box and remove
static rods. Sterilize by running 70% ETOH through the scaffolds in seeding mode for 30 min. Rinse 3
times with PBS and wet with cell media 24 hrs prior to seeding.
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Calculating cell coverage with ImageJ

1) The examined scaffolds are cut vertically into five samples and each sample is SEM imaged in a 3x3 grid at
300x.
2) The images are processed with DiameterJ Segment for thresholding.Images that show the most accurate
representation of cell coverage are manually chosen, then placed into the “Best Segmentation” folder
created by the diameter program. (The segmented image should remain open on ImageJ and should have
the cell coverage appearing in black, if not invert the image.)
3) Then, go to Process > Binary > Watershed, and to Analyze > Analyze Particles to measure the amount of
cell coverage (black space) present from the segmented images.
(A command window will appear, for the “Size” parameter. In the experiment, it was concluded that
images, primarily in drip seeding and counterpart, were best represented with a pixel size of 800 inch 2. The
images with little to no surface coverage were best analyzed with the selection tool brush to manually select
the cell coverage. For images that are entirely covered with cells, mainly dynamic seeding, it was best to
use a pixel size of 60 inch2. The smaller size ensures that the cells with little surface area are being included
in the overall area percentage.)
4) Once the accurate pixel size is chosen, the “Show” option will have a drop-down arrow and “Overlay
Masks” will be selected. This ensures that the highlighted surface coverage image appears. Also, the “Pixel
units” and “Summarize” options should be checked. Once all the parameters are chosen, click OK. An
output of the percent area and a highlighted image of the counted patches will pop up.

5) The area percentages can be saved as an excel file, once the results of all nine images are saved into the
same spreadsheet, they are placed into a separate excel spreadsheet named “% Area Coverage”. In that
spreadsheet, the surface area is placed in cells corresponding to their location on the scaffold. Once the
entire scaffold is processed, the excel spreadsheet (% Area Coverage) will display a visual representation of
the cell coverage for each of the seeding mechanisms.
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